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following HER2/neu pathway inhibition and is spontaneously up-regulated during tumor recurrence in
multiple genetically engineered mouse models for breast cancer. We find that Cerk is rapidly up-regulated
in tumor cells following HER2/neu down-regulation or treatment with adriamycin and that Cerk is required
for tumor cell survival following HER2/neu down-regulation. Consistent with our observations in mouse
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expression is associated with an increased risk of recurrence in women with breast cancer. Additionally,
although CERK expression is associated with aggressive subtypes of breast cancer, including those that
are ER-negative, HER2-positive, basal-like, or high grade, its association with poor clinical outcome is
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ABSTRACT
ROLE OF CERAMIDE KINASE IN BREAST CANCER PROGRESSION

Ania Warczyk Payne
Lewis Chodosh, M.D., Ph.D.

Recurrent breast cancer is typically an incurable disease and, as such, is
disproportionately responsible for deaths from this disease. Recurrent breast cancers arise from
the pool of disseminated tumor cells (DTCs) that survive adjuvant or neoadjuvant therapy, and
patients with detectable DTCs following therapy are at substantially increased risk for
recurrence. Consequently, the identification of pathways that contribute to the survival of
breast cancer cells following therapy could aid in the development of more effective therapies
that decrease the burden of residual disease and thereby reduce the risk of breast cancer
recurrence. We now report that Ceramide Kinase (Cerk) is required for mammary tumor
recurrence following HER2/neu pathway inhibition and is spontaneously up-regulated during
tumor recurrence in multiple genetically engineered mouse models for breast cancer. We find
that Cerk is rapidly up-regulated in tumor cells following HER2/neu down-regulation or
treatment with adriamycin and that Cerk is required for tumor cell survival following HER2/neu
down-regulation. Consistent with our observations in mouse models, analysis of gene
expression profiles from over 2,200 patients revealed that elevated CERK expression is
associated with an increased risk of recurrence in women with breast cancer. Additionally,
although CERK expression is associated with aggressive subtypes of breast cancer, including
those that are ER-negative, HER2-positive, basal-like, or high grade, its association with poor
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clinical outcome is independent of these clinicopathological variables. Together, our findings
identify a functional role for Cerk in breast cancer recurrence and suggest the clinical utility of
agents targeted against this pro-survival pathway.
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CHAPTER 1: Breast Cancer Progression, Sphingolipids and Cerk
Breast Cancer
Breast cancer is the most common cancer diagnosed and the leading cause of cancerrelated death among women worldwide (1). In general, primary tumors can be effectively
treated by the combination of surgery, radiotherapy, and adjuvant hormonal therapy,
chemotherapy and/or treatment with targeted therapies, and this has resulted in 5-year survival
rates for this disease that approach 90% (1). Despite this favorable short-term prognosis,
however, many breast cancer survivors relapse with recurrent disease, sometimes up to 20
years after their initial diagnosis and treatment. Since recurrent breast cancers can be treated,
but not cured, the re-emergence of tumors following therapy is responsible for the majority of
morbidity and mortality associated with this disease.
There are many risk factors known to increase susceptibility to breast cancer. Nongenetic risk factors include gender, age, age at menarche, age at first birth, parity,
breastfeeding, menopause and hormonal therapy. Women are 100 times more likely to be
diagnosed with breast cancer than men (2). Age is the second strongest risk factor for breast
cancer, with 11.4% of breast cancers found in women younger than 45, while 66.4% of breast
cancers are found in women age 55 or older (2). Lifestyle factors such as tobacco and alcohol
use as well as obesity and physical inactivity can also increase risk of developing breast cancer
(3–5).
Genetic susceptibility is manifested as familial clustering of breast cancer; having a firstdegree relative with breast cancer doubles a woman’s risk of developing this disease (6).
Between 5 and 10% of breast cancers are believed to originate from germline mutations, with
the majority arising from mutations in the BRCA1 and BRCA2 genes, which can increase risk up
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to 85% (7). Other genes whose germline mutations predispose women to breast cancer include
TP53, PTEN, STK11, CDH1, ATM and CHEK2.
In an attempt to predict outcome and response to therapy, breast cancers have
historically been classified based on histology into ductal or lobular subtypes, and also based on
expression of estrogen receptor (ER), progesterone receptor (PR), and HER2/neu into three
groups: ER+, HER2+ and triple-negative breast cancer (TNBC). Other prognostic factors that
categorize patients as having high risk of relapse include positive lymph node involvement, high
tumor grade and large tumor size (8,9). Recently, there has been a transition to a classification
system based on differentiation state and gene expression profiling, leading to categorization
into the following molecular subtypes: luminal A and luminal B (both subsets of ER+ tumors),
ErbB2+ (which correlates broadly with HER2+ classification), basal and claudin-low (both subsets
of triple-negative breast cancer), and normal-like.
One of the most common oncogenes driving spontaneous breast cancer is human
epidermal growth factor 2 (HER2/neu). It is genetically amplified or overexpressed in 15-20% of
breast cancers (10). Soon after its identification, HER2/neu amplification was shown to be
strongly predictive of poor recurrence-free survival, poor overall survival, and relapse,
independent of other prognostic factors (11,12). HER2/neu, also known as ErbB2, is a receptor
tyrosine kinase of the ErbB family, which also includes EGFR (HER1 or ErbB1), HER3 (ErbB3), and
HER4 (ErbB4). All four members have an extracellular ligand-binding domain, a membranespanning domain, and a cytoplasmic tyrosine-kinase domain. Under normal conditions, the
spatial and temporal expression of ErbB ligands, which include EGF, TGF-α, neuregulins and
other EGF-family growth factors, regulate activation of the ErbB receptors. Ligand binding to
ErbB receptors induces the formation of homo- and heterodimers, which leads to activation of
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the intrinsic kinase domains. HER2/neu does not have any known ligands, but is the preferred
dimerization partner for the other three ErbB receptors, and under physiological conditions
requires heterodimerization with another family member for activation. However, when
HER2/neu is overexpressed, such as in HER2/neu-amplified breast cancers, it accumulates at the
plasma membrane and becomes able to form constitutively activated homodimers. Receptor
dimers become phosphorylated on specific tyrosine residues within the cytoplasmic tail, leading
to activation of signaling cascades downstream. The main signaling pathways activated by ErbB
receptors are the PI3K/AKT and the RAS/RAF/MAPK pathways. Other important ErbB signaling
effectors are the STATs, SRC tyrosine kinase, and mTOR (13).

Targeted Therapies and Resistance in Breast Cancer
Targeted therapies against HER2/neu are now part of the standard of care for patients
with HER2+ breast cancer, and have achieved significantly improved outcomes for these
patients. Three targeted agents against HER2/neu are currently approved by the FDA:
trastuzumab (Herceptin®, Genentech), pertuzumab (PerjetaTM, Genentech), and lapatinib
(Tykerb®, GlaxoSmithKline). Trastuzumab is a humanized monoclonal antibody with an IgG1 Fc
structure, which binds subdomain IV of the HER2/neu extracellular domain. Currently,
trastuzumab is the only adjuvant therapy approved by the FDA for patients with HER2+ early
breast cancer (EBC), after completion of chemotherapy (14). It is also indicated for metastatic
breast cancer (MBC) patients in combination with paclitaxel or docetaxel after completion of a
course of doxorubicin and cyclophosphamide, or concurrent with carboplatin and docetaxel.
When combined with chemotherapy, trastuzumab has been shown in large clinical trials to
significantly extend disease-free survival (DFS) and overall survival (OS) (15–17). Trastuzumab’s
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complex mechanism of action has been the source of some debate, but is thought to include (1)
disruption of ligand-independent heterodimerization of HER2/neu and HER3, (2) prevention of
proteolytic cleavage of the HER2/neu extracellular domain (which generates a constitutively
active form of the receptor), and (3) antibody-dependent cell-mediated cytotoxicity (ADCC),
mediated by natural killer cells (18). Downstream effects of these mechanisms include reduced
PI3K/AKT and MAPK signaling (19), enhanced nuclear import and stabilization of CDK inhibitor
p27Kip1, reduced secretion of angiogenic factors (20), and impaired DNA damage response (21).
Lapatinib is a small molecule competitive dual tyrosine kinase inhibitor of EGFR and
HER2/neu. In a large clinical trial, it has demonstrated efficacy in combination with capecitabine
in HER2+ MBC that has progressed after treatment with trastuzumab, anthracyclines and
taxanes (22). Pertuzumab is a humanized monoclonal antibody that acts as a HER2/neu
dimerization inhibitor, but clinical trials evaluating efficacy in MBC have not been successful to
date.
In patients with MBC, response to trastuzumab and lapatinib tends to be temporary. In
EBC, although some patients treated in the adjuvant setting will demonstrate pathologic
complete response (pCR), it is expected that a fraction will eventually relapse. This suggests that
tumors harbor acquired mechanisms of resistance to these targeted therapies (18,23).
Resistance to these therapies can be intrinsic or acquired, and there are many mechanisms that
have been described. One mechanism is through mutation or truncation of the HER2/neu
receptor itself, including the C-terminal truncation mutant p95-HER2 (24,25) and the exon 16
truncation mutant Δ16-HER2 (23). Another common mechanism of resistance to HER2/neu
targeted therapies is activation of parallel bypass signaling pathways. This can happen in many
ways, including (1) activation of other receptor tyrosine kinases, specifically EGFR, HER3, HER4,
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IGF-1R (18), or c-MET, (2) increasing HER-family ligands, including TGF-α (18), EGF, betacellulin
or heregulin, (3) hormone receptor expression, (4) activation of intracellular kinases or
deactivation of intracellular phosphatases, which can manifest as gain of function mutations in
PIK3CA (p110a) (seen in approximately 25% of breast cancers (26)), AKT1, or PIK3R1 (p85a), or
loss of function mutations in PTEN (seen in approximately 40% of breast cancers (26)), or in the
tumor suppressor INPP4B (23). Resistance to targeted anti-HER2/neu therapies can also come in
the form of defects in apoptosis and cell cycle control, including modifications in BIM, Survivin,
or p27Kip1 (27,28). Lastly, resistance to trastuzumab can come in the form of ADCC Resistance,
which is frequently attributable to polymorphisms in FcR genes (23).
Many clinical trials are attempting to combat the widespread resistance to targeted
therapy by utilizing various strategies. The ALTTO (Adjuvant Lapatinib and/or Trastuzumab
Treatment Optimization) and NeoALTTO trials are evaluating combining lapatinib and
trastuzumab for EBC (29), and have demonstrated improved rates of pCR with both targeted
therapies used in combination. In the CLEOPATRA (Clinical Evaluation of Pertuzumab and
Trastuzumab) trial, the addition of pertuzumab to trastuzumab and docetaxel was evaluated for
HER2+ MBC (30,31), and it demonstrated significantly improved progression-free survival as well
as overall survival. Other strategies to combat resistance include the conjugation of trastuzumab
to an inhibitor of microtubule polymerization (trastuzumab-DM1), combining trastuzumab with
an anti-VEGF antibody bevacizumab, using HSP90 antagonists (tanespimycin or restapimycin)
(32,33), or the use of aromatase inhibitors (anastrozole or letrozole).
Compounding the issue of resistance to targeted therapy in breast cancer patients is the
problem of multidrug resistance (MDR) to chemotherapy. Systemic agents are active at the
beginning of therapy in 90% of primary breast cancers but only in 50% of MBC (34). Mechanisms
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of resistance to chemotherapy are varied and include: (1) decreased drug uptake (via decreased
expression of transporters or defective endocytosis); (2) increased drug efflux (through ABC
transporters, RLIP76/RALBP1, or ATP7A/B); (3) alterations in lipid metabolism (particularly
ceramide metabolism, discussed in detail below, affecting both membrane structure and cell
signaling); (4) activation of detoxifying systems, including extra-hepatic drug metabolism
(expression of phase I cytochrome P450 enzymes or phase II conjugation enzymes); (5)
activation of DNA repair mechanisms; and (6) evasion of drug-induced apoptosis (through upregulation of BCL2-family proteins) (35). The classic model of MDR involves drug efflux by Pglycoprotein or Multidrug Resistance Protein 1 (MRP1), changes in topoisomerase II, or
modifications in glutathione S-transferase activity.
Although advances in screening and therapy have led to significant improvements in
clinical outcome for breast cancer patients, up to 30% of them will eventually relapse with the
appearance of recurrent tumors (36). Breast cancer relapse can occur early, with a peak at
about 18 months post-surgery, or much later with a second peak at 60 months with a tapered
plateau extending up to 15 years (37). Breast cancer has a particular propensity for late
recurrence, with some relapses occurring up to 25 years after initial diagnosis and treatment
(9,37–39). To mathematically model how recurrences can arise after such a long period of
remission, continuous tumor growth models had to be modified to account for a period of
dormancy (40).
Recurrent breast cancers arise from the pool of disseminated tumor cells (DTCs), termed
minimal residual disease, that survive therapy in their host presumably due to some intrinsic
resistance mechanisms. DTCs can be identified in a substantial fraction of breast cancer patients
at the time of diagnosis, even those with early stage disease (41) and predict poor disease-free
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survival and overall survival (42–44). Nevertheless, despite the clinical importance of DTCs, the
mechanisms that underlie their survival and their formation of recurrent tumors following
therapy are largely unknown.

Mouse Models of Breast Cancer Recurrence
In order to dissect the mechanisms contributing to breast cancer recurrence, we have
employed inducible transgenic mouse models of breast cancer that recapitulate critical features
of disease progression as it occurs in patients. In this system, the doxycycline-dependent,
mammary-specific expression of oncogenes relevant to human breast cancer, including
HER2/neu, c-MYC, Wnt1 and Akt1, results in the formation of invasive mammary
adenocarcinomas (45–49). Furthermore, in a manner analogous to the treatment of cancers
with targeted therapies such as trastuzumab, mammary tumors regress to a non-palpable state
following oncogene down-regulation induced by doxycycline withdrawal. Similar to breast
cancer patients, however, mice bearing primary tumors that have regressed following oncogene
down-regulation often develop recurrent tumors after a variable period of dormancy.
Moreover, since recurrent tumors typically arise in the absence of re-expression of the initiating
oncogene, the survival and growth of recurrent tumor cells is ostensibly driven by the activation
of alternate escape pathways, as is commonly observed in cancer patients treated with targeted
therapies. As such, these genetically engineered mouse models provide a platform with which to
investigate the cellular and molecular mechanisms that contribute to tumor recurrence, thereby
identifying essential pathways that may be amenable to therapeutic targeting.
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Sphingolipids
In recent years, sphingolipids have emerged as important regulators of tumor cell
survival, as well as a number of other pathophysiological processes relevant to cancer, including
proliferation, migration and inflammatory signaling. Sphingolipids represent 10-20% of cellular
lipids, and have structural roles in membranes as well as cellular signaling roles that are the
subject of intense ongoing investigation. Mammalian sphingolipids have an 18-carbon chain
sphingoid backbone attached to a head group and are conjugated to an acyl group of varying
carbon chain length (50). Sphingolipids are unique lipids in their use of the amino acid serine as
the backbone to which acyl chains are attached (51). As the origin of their name suggests (the
prefix sphingo means “Sphinx-like”, referring to the riddles posed by the Sphinx), the functions
of sphingolipids have been enigmatic since their discovery in 1884. Today, sphingolipids retain a
high level of complexity for three reasons: (1) there are a large number of distinct sphingolipids
that can be generated by modifications of the sphingoid backbone, (2) most sphingolipids are
synthesized by interconversion reactions catalyzed by enzymes maintaining cellular
homeostasis, and (3) sphingolipid metabolism is extremely compartmentalized within different
cellular membranes (50). A model for cellular homeostasis maintained by sphingolipid
metabolism is known as the “sphingolipid rheostat”. Sphingolipid metabolism is in constant flux
and regulates cellular fate by balancing pro-survival and pro-apoptotic sphingolipids (50).
Sphingolipids have been implicated in an array of physiological and pathological
processes. They were first characterized as having a role in membrane structure. An increase in
sphingolipid content from the endoplasmic reticulum to the Golgi to the plasma membrane
leads to membrane thickening, which is proposed to control vesicular trafficking and protein
sorting through the secretory pathway, as well as the endocytic pathway (51,52). Sphingolipids
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and cholesterol have been shown to self-associate to form dynamic, laterally segregated
membrane microdomains or “lipid rafts” that act as platforms regulating diverse membrane
proteins including signaling receptors (such as Fas (53)) by aggregating them, leading to
activation and enhanced signaling (51,54). Glycosphingolipids have been implicated in cell
adhesion, as binding between glycosphingolipids and lectins is important for the association of
myelin with nerve fibers, the formation of nodes of Ranvier, and neutrophil adhesion to the
endothelium (51,55). Furthermore, sphingolipids have been implicated in regulation of the cell
cycle, cell growth and proliferation, angiogenesis, differentiation and senescence.
Pathological roles for sphingolipids have been described in metabolic disorders,
inflammatory diseases, cancer and sphingolipidoses (genetic defects that lead to abnormal
metabolism of sphingolipids and their deposition in neural tissues that results in severe mental
retardation (56)). Sphingolipids have been thoroughly investigated for their role in
inflammation. The first evidence that sphingolipids could play a role in inflammation came from
studies using TNFα, demonstrating it activates A-SMase, inducing ceramide production and
activation of NF-κB (57). NF-κB is a transcription factor that regulates many genes with
important roles in inflammation such as cytokines, chemokines, and pro-inflammatory enzymes
such as COX-2 (58). Ceramide can also activate C/EBP transcription factors to induce expression
of inflammatory genes such as TNF, IL-6, IL-8 and IL-1β (59). Some of the effects of ceramide in
inflammation may, in fact, be attributable to C1P or S1P, which were poorly characterized at the
time of the studies performed with ceramide. C1P has been demonstrated to directly activate
cPLA2 leading to arachidonic acid release from membranes and downstream eicosanoid
formation, specifically PGE2 (60). A coordinated response of S1P-induced COX-2 up-regulation
with C1P-induced cPLA2 activation has recently been characterized (61). Mast cell degranulation
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stimulates inflammatory responses by releasing pro-inflammatory factors from vesicles. C1P
stimulates mast cell degranulation in a Ca2+-dependent manner, and may enhance fusion of
vesicles with the plasma membrane (62). Mast cell stimulation by engagement of the highaffinity IgE receptor FcεRI leads to activation of SphK and production of S1P. S1P in turn gets
secreted and in an autocrine manner binds the S1P receptors expressed on mast cells, S1PR1
and S1PR2, leading to migration and degranulation (63). Due to its role in mast cell activation,
S1P has been implicated in airway hyperresponsiveness, allergy and asthma (64,65).
Sphingolipids, particularly ceramide, have been shown to have an important role in
cancer, specifically in regulation of cancer cell growth, differentiation, senescence and apoptosis
(53). In fact, an inverse correlation has been found between levels of ceramide and the degree
of malignant progression in patients with malignant astrocytomas (66). Ceramide metabolism
has been implicated in cancer drug resistance, as decreased levels of endogenous ceramide
caused by increased expression of glucosylceramide synthase (GCS) results in the development
of a multidrug resistant (MDR) phenotype in many cancer cells (67).

Ceramide
De novo sphingolipid production begins in the endoplasmic reticulum with the synthesis
of two main precursors: long-chain bases (LCBs) and very-long-chain fatty acids (VLCFAs) of
various chain lengths (51). Condensation of L-serine and fatty acid-CoAs catalyzed by serine
palmitoyltransferase (SPT) forms 3-ketosphinganine (also referred to as 3-ketodihydrosphingosine) (Figure 1.1). 3-ketosphinganine is reduced by 3-ketosphinganine reductase
to sphinganine (also known as dihydrosphingosine). Sphinganine is then N-acylated by
(dihydro)ceramide synthase to dihydroceramide. There are six distinct ceramide synthase
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enzymes encoded by six genes, each of which has activity only against sphinganines of specific
chain lengths (68). Together they generate upwards of 50 different molecular species of
dihydroceramide. Dihydroceramide is desaturated by dihydroceramide desaturase (DES) to
ceramide (53) (Figure 1.1). Ceramide is then transported by vesicular and non-vesicular means
to the Golgi, where it is further elaborated at the headgroup position to generate a large variety
of sphingolipids (51). Ceramide can be trafficked from the endoplasmic reticulum to the Golgi by
vesicular transport or by ceramide transport protein (CERT) (69), a soluble protein regulated by
sphingolipid levels that extracts ceramide from endoplasmic reticulum membranes directly and
delivers it to the Golgi (51,70). Although some controversy still exists on this matter, ceramide
trafficked by vesicular transport and by CERT appears to have different fates and be
compartmentalized within the Golgi. In the Golgi, sphingomyelin synthases and a range of
glycosylation enzymes generate diverse glycosphingolipids and sphingomyelin (ceramide
conjugated to a phosphocholine moiety) (51). The vast majority of ceramide is converted to
sphingomyelin (SM) (71), in which it is believed to be stored for rapid generation of ceramide by
sphingomyelinases upon stimulation.
Ceramide is the most basic sphingolipid, containing the requisite sphingosine backbone,
a fatty acid side chain and a hydrogen atom as the head group (50). As such, ceramide
represents the core structure of most cellular sphingolipids and is the key node in sphingolipid
metabolism (51). Once incorporated into a large array of complex sphingolipids within cellular
membranes, ceramide can be released by hydrolysis of the head group, but its range of activity
is restricted locally due to its hydrophobic nature. As a result, different pools of ceramide are
thought to be important for specific functions in each subcellular compartment (50).
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Despite the many roles for sphingolipids in membrane structure and signaling, the way
cells sense and regulate their overall levels is poorly characterized. Serine Palmitoyltransferase
(SPT)-mediated condensation of serine with fatty acid-CoAs to generate LCBs and VLCFAs is the
first and rate-limiting step in sphingolipid synthesis and is therefore a crucial point of regulation
(51). In the endoplasmic reticulum, ORM proteins form an inhibitory multiprotein complex with
SPT called the SPOTS complex (Serine Palmitoyltransferase, ORM1/2, TSC3, and SAC1) (51,72),
without which cells accumulate toxic levels of sphingolipids. Further downstream, production of
ceramides by ceramide synthase is also subject to tight regulation involving a complex balance
between the six isoforms (51). In addition to transcriptional regulation, ceramide synthase
activity was recently found to be modulated by reversible dimerization (51,73).
Ceramide plays a central role in sphingolipid signaling, and its accumulation has been
demonstrated to play an important role in mediating apoptosis in tumor cells in response to
chemotherapy (74–77), radiotherapy (78–81) and, more recently, targeted therapy (82–86). In
response to therapy and other cellular stresses, ceramide can be generated by the de novo
pathway (described above), or more rapidly by the activity of sphingomyelinases (SMases).
SMases hydrolyze the phosphodiester bond of sphingomyelin to liberate ceramide by cleavage
of the phosphorylcholine head group (50). Acid sphingomyelinase (A-SMase) is present in
lysosomes and has a pH-optimum of 5.0. Neutral sphingomyelinase (N-SMase) is typically active
in mitochondria and activated by ROS, and has a pH-optimum of 7.4. N-SMase requires reactive
oxygen species (ROS) for activation, linking oxidative injury to ceramide formation (53,87). Both
isoforms of SMase can be found at the plasma membrane – A-SMase at the outer leaflet and NSMase at the inner leaflet. A-SMase was shown to be required for accumulation of ceramide
following ionizing radiation (53,88). In fact, A-SMase deficiency, as seen in the lysosomal storage
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disorder Niemann-Pick disease, results in resistance to radiation-induced apoptosis (50).
Niemann-Pick disease also leads to excessive accumulation of sphingomyelin that can be toxic to
cells, specifically neurons, leading to cell death. This results in severe neurological disease that
leads to early death in most patients.
Ceramide accumulation induced by either isoform of SMase has been implicated in the
induction of apoptosis. Numerous studies support that ceramide is important in the apoptotic
response of cancer cells to death inducers such as FAS/FAS ligand, TNFα, growth factor
withdrawal, hypoxia and DNA damage (53,89). Ceramide can mediate apoptosis through the
extrinsic and intrinsic pathways with both structural and signaling roles. Ceramide generated at
the plasma membrane by A-SMase is incorporated into ceramide-enriched membrane platforms
that help cluster death receptors, increasing formation of death-inducing signaling complexes
(DISCs) and leading to induction of apoptotic signaling cascades (90,91). Ceramide can also
induce mitochondrial outer membrane permeabilization, a hallmark of the intrinsic pathway of
apoptotic signaling, by forming ceramide channels (92,93).

Ceramide Signaling Pathways
In addition to its structural roles in membranes, ceramide has been found to have many
important signaling roles in response to stress stimuli, most of which result in induction of
apoptosis, differentiation, or senescence. Which outcome is obtained depends on cell type, as
ceramide acts preferentially on cancer cells to induce apoptosis and on non-transformed cells to
induce cell-cycle arrest and/or senescence (53). The first signaling targets of ceramide to be
characterized were named ceramide-activated protein phosphatases (CAPPs), and were later
identified as PP1 and PP2A (94), whose downstream targets include RB, BCL2, c-JUN, PKCα, AKT,
13

and SR proteins (which modulate mRNA splicing) (95). Dephosphorylation of these targets by
PP1 and PP2A leads to inhibition of pro-survival and mitogenic pathways and sensitization to
apoptosis or cell cycle arrest. In response to TNFα, ceramide activates PP1 leading to RB
dephosphorylation, which induces G0/G1 arrest in MOLT-4 acute lymphoblastic leukemia cells
(96). Also through PP1, ceramide has been shown to lead to dephosphorylation and inactivation
of CDK2, but interestingly not CDK4 (53,97). Additional studies showed that ceramide induces
up-regulation of the CDK inhibitors p21WAF1 in Wi-38 human fibroblasts and p27KIP1 in
nasopharyngeal carcinoma cells (53,97,98). Examination of the role of ceramide in senescence
demonstrated that fibroblasts have increased ceramide levels when they become senescent,
and furthermore that treatment with exogenous ceramide induces senescence (53,99). The
mechanism of ceramide-induced senescence involves inhibition of phospholipase D,
diacylglycerol generation, and activation of PKC, which leads to suppression of mitogenic
pathways (53,99).
Kinase targets of ceramide include stress-activated protein kinases (SAPKs) such as the
jun kinases (JNKs), kinase suppressor of Ras (KSR), and the atypical protein kinase C (PKC)
isoform, PKCζ (100). Ceramide is thought to activate SAPK signaling via PKCζ, RAC-1 or TAK-1
(100,101). JNK signaling has been shown to be required for stress-induced ceramide
accumulation (102), and activation of this pathway can lead to apoptosis or cell cycle arrest
(100,101). The p38 SAPK, also activated by ceramide, phosphorylates the transcription factors
CREB and ATF-1 (100,103). The first non-SAPK enzyme to be identified as a ceramide-activated
protein kinase (CAPK) was KSR. KSR activates MAPK, RAF1, PKCζ, and MEKK (53,89), leading to
pro-apoptotic signaling. Ceramide has also been shown to activate PKR, the dsRNA-dependent
protein kinase, through RAX, the cellular PKR activator (104). Once activated, PKR
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phosphorylates eIF2α, leading to inhibition of protein translation (105), which if sustained can
lead to apoptosis.
Another downstream signaling effector of ceramide is the endolysosomal aspartate
protease cathepsin D, which is activated by ceramide generated in lysosomal membranes.
Cathepsin D leads to BID-mediated activation of caspase-9 and caspase-3 (53,106). This connects
lysosomal ceramide formation to the mitochondrial pathway of apoptosis.

Ceramide Metabolism
In light of the importance of ceramide in apoptosis induced by anti-neoplastic therapies
and in resistance to therapy, ceramide metabolites have been the focus of increasing attention.
Amongst the best-characterized metabolites of ceramide are glucosylceramide, sphingosine-1phosphate (S1P), sphingomyelin (SM), and ceramide-1-phosphate (C1P) (Figure 1.1) (53,107).
Together, these metabolites decrease levels of apoptotic ceramide and exert anti-apoptotic
functions of their own (108).
Glucosylceramide is synthesized by glucosylceramide synthase (GCS), which catalyzes
the transfer of a glucose molecule from UDP-glucose to the primary hydroxyl of ceramide to
generate glucosyl β1-1 ceramide (109), the first step in glycolipid biosynthesis. Glucosylceramide
is the precursor for 90% of glycosphingolipids; the remaining 10% come from the precursor
galactosylceramide, which is generated by galactosylceramide synthase (Figure 1.1) (109).
Glycosphingolipids (GSLs) represent more than 3000 molecular species that contain between
one and eight sugars moieties. GSLs are clustered with sphingolipids and other membrane
components to form GSL-Enriched Microdomains (GEMs) a type of lipid raft in the plasma
membrane (69,110). As described above, GSL- and sphingolipid-containing lipid rafts modulate
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membrane transport, signal transduction, and cell-cell interactions, modulating cell responses to
stress and playing key roles in development of drug resistance (54,69).
GCS has been shown to impart resistance to apoptosis to cancer cell lines in the context
of cancer therapy in vitro (reviewed in (69)). However, it has not been shown to be explicitly
involved in tumorigenesis or tumor progression in vivo. High GCS is the cause of drug resistance
in more than 14 cancer cell lines of human breast, ovarian, colon, and cervical cancers, and
leukemia (69,83). Multidrug resistant (MDR) cells selected by doxorubicin, paclitaxel,
vinblastine, or imatinib overexpress GCS at levels 2- to 4-fold higher than drug-sensitive
counterparts (69). Furthermore, silencing or inhibition of GCS sensitizes resistant cell lines to
more than 20 anticancer agents including doxorubicin, paclitaxel, cisplatin, vinblastine and
imatinib (69). Blocking ceramide glycosylation by inhibiting GCS in can result in increased levels
of ceramide and decreased levels of GSLs, sensitizing cancer cells to chemotherapy (69).
Treatment with exogenous ceramide using polymeric nanoparticles can overcome multidrug
resistance, providing further evidence that GCS metabolism of ceramide inhibits apoptosis,
underlying acquired drug resistance in these cell lines (69,111).
GCS may have a functional role in human cancers, as levels of GCS mRNA or protein
were found to be elevated four-fold in approximately 80% of advanced breast cancers (69,112).
Elevated GCS expression is associated with ER-positive breast cancer, though GCS expression
was not found to be predictive of DFS in either ER-positive or ER-negative breast cancer patients
(113). Ceramide glycosylation by GCS is enhanced in breast cancer stem cells (BCSCs) but not in
normal mammary epithelial cells, and is thought to be implicated in maintaining tumorous
pluripotency of BCSCs (114).
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Because it has been implicated in multidrug resistance in many contexts, GCS has
become of interest as a drug target in cancer. “P-drugs”, including PPMP, PDMP, and PPPP, are a
family of potent GCS inhibitors that are glucosylceramide mimetics containing a phenyl ring in
place of the aliphatic portion of the sphingosine backbone (115). GCS inhibition by PPMP was
shown to lead to failure of cleavage furrow ingression and cytokinesis due to ceramide
accumulation, demonstrating that the balance of ceramides to glucosylceramides is crucial for
effective cytokinesis (116).
Recently, Genzyme Corporation developed and tested a set of ethylenedioxy-PPPP
analogs as highly potent and selective GCS inhibitors (115). These inhibitors have been indicated
for the treatment of type 1 Gaucher disease in what is known as substrate reduction therapy
(SRT), but could potentially be useful in the treatment of multidrug resistant or refractory
cancers in combination with chemotherapy. Gaucher disease is an autosomal recessive genetic
disorder caused by an inactivating mutation in the GBA gene, which encodes the enzyme
glucocerebrosidase. Glucocerebrosidase cleaves glucosylceramide to release a glucose molecule
and ceramide, therefore its deficiency leads to toxic accumulation of glucosylceramide. Typical
manifestations of Gaucher disease include anemia, thrombocytopenia, hepatosplenomegaly,
and bone pathology. Some patients also develop pulmonary or neurologic symptoms (117).
Genzyme Corporation’s N-octanoyl derivative of PPPP named Genz-112638 (Eliglustat tartrate)
(118) underwent clinical trials (119), and N-butyl-deoxynojirimycin (NB-DNJ) has been
commercialized (miglustat, Zavesca®) as SRT for type 1 Gaucher disease (120). Although the
development of GCS inhibitors has been used mostly in the context of Gaucher disease, it still
holds promise as a target in drug resistant cancers in combination with chemotherapy.

17

Another important and well-characterized metabolite of ceramide is S1P. S1P is
generated by the deacylation of ceramide into sphingosine by ceramidase followed by
phosphorylation by sphingosine kinase (SphK). S1P and SphK have been implicated in many
cellular processes including cell growth, proliferation, survival and migration. The functions of
S1P and SphK in cancer, including in tumorigenesis and resistance to therapy, have been
extensively characterized and have led to development of many inhibitors of that pathway
(reviewed in (121)). S1P has many intracellular roles, including activating NF-κB and inducing
COX-2 expression, as well as paracrine and autocrine roles involving stimulation of G-protein
coupled receptors (GPCRs) called S1P receptors (S1PRs). Activation of S1PRs has been implicated
in cell motility as well as proliferation (122). S1P has been defined as a tumor-promoting lipid
(53) implicated in cell growth, survival, apoptosis, invasion, vascular maturation, and
angiogenesis (123).
SphK has been defined as an oncogene, though no evidence has been found of
mutations in cancer (121). SphK has, however, been found to be up-regulated in many cancers
including stomach, lung, brain, colon, kidney and breast cancer and in non-Hodgkin’s lymphoma
(121,124). Elevation of SphK1 in various cancers implies that it could be a molecule of prognostic
value (125), and in fact, high SphK is associated with ER-negative status and predicts poor DFS in
ER-positive breast cancer patients (126). However, SphK was not found to be predictive of OS or
DFS in a prospective neoadjuvant chemotherapy trial (GeparDuo) (127). Animal studies have
confirmed SphK to be pro-tumorigenic in orthotopic breast and prostate mouse tumor models
(128,129). Additionally, S1P signaling has been implicated in the development of drug resistance
in multiple cancer cell lines (82,130). Overexpression of SphK in breast cancer cells results in
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increased proliferation and resistance to tamoxifen-induced growth arrest and apoptosis (131),
and confers resistance to other anti-cancer drugs, sphingosine and TNFα (125,129,132).
Many therapeutics against SphK are in development, including S1P-specific antibodies,
small molecule inhibitors of SphK, and S1P receptor-directed agents (121). Safingol, a small
molecule inhibitor of SphK, is in clinical trials in combination with Cisplatin in advanced solid
tumors, where it was found to decrease plasma levels of S1P and prolong stable disease,
inhibiting cancer progression (133). These findings suggest the potential utility of targeting
ceramide metabolism, particularly SphK, in cancer therapy.
Sphingomyelin (SM) is the most abundant sphingolipid and metabolite of ceramide
(134), synthesized by the transfer of phosphorylcholine from phosphatidylcholine to ceramide
by sphingomyelin synthase (SMS) (108), yielding mitogenic diacylglycerol (DAG) in the process
(71). Cellular pools of SM are thought to act as a reservoir for rapid release of ceramide by
SMases in response to cellular stresses (71,135,136). Production of SM occurs mostly in the
trans-Golgi, where it forms microdomains that affect the organization of other membrane
molecules, and helps establish compositional and functional differences between the
endoplasmic reticulum, Golgi and plasma membranes (71,137). SM accumulates in the
exoplasmic leaflet of the plasma membrane, where high packing density and affinity for
cholesterol helps to create a rigid barrier to the extracellular environment. SM synthesis in the
Golgi also creates a local pool of DAG, which recruits PKD and leads to formation of secretory
vesicles (71,138). SMS regulates levels of pro-apoptotic ceramide and mitogenic DAG in opposite
directions, so it may have a direct impact on proliferation and apoptosis (71,139,140). Up- or
down-regulation of SMS activity has been linked to mitogenic and pro-apoptotic signaling in a
variety of cell types (71,139,141,142), though the mechanisms remain unclear.
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Ceramide Kinase
Ceramide Kinase (Cerk), the only enzyme known to generate ceramide-1-phosphate
(C1P), was identified in 1989 by Bajjalieh and colleagues from rat brain synaptic vesicles (143),
and was subsequently found in human leukemia (HL-60) cells (144), where C1P was first
described (145). Cerk was identified based on its homology with the catalytic domain of DAGkinase, as Cerk contains a DAG-kinase domain. Cerk introduced new subclass of the DAGK family
distinct from sphingosine kinases (146), as it has no activity toward sphingosine. Cerk is a 60 kDa
protein encoded by 537 amino acids in humans and 531 amino acids in mice, with the sequence
identity between hCerk and mCerk being 84.4% (147). Due to the presence of a Pleckstrin
Homology (PH) domain in its N-terminus between residues 8 and 124 (148), Cerk is exclusively
membrane associated. Deletion of the PH domain has been demonstrated to ablate activity and
localization to the Golgi and plasma membranes (149). The leucine 10 residue in the PH domain
is essential for catalytic activity (150), and the β6-β7 loop bridging the two beta strands of the
PH domain is essential for both localization and activity (151). Sequences outside of the PH
domain are also required for proper localization and activity (152), and the interaction between
the PH domain and PIP2 regulates plasma membrane targeting of Cerk as well as C1P levels
(148). N-terminal myristolation of Cerk has been shown not to be required for localization or
activity.
Cerk contains a calmodulin (CaM) binding motif encompassing amino acid residues 422435 in its C-terminus (150). CaM binds directly to this site in a Ca2+-dependent manner (153),
acting as Ca2+ sensor for Cerk (146). The binding of CaM to Cerk is regulated by Cerk
phosphorylation at serine 427 (154), which is a putative PKA phosphorylation site (154). Cerk
activity is enhanced by increases in Ca2+ levels, and association with a Ca2+/CaM complex is
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necessary for activity (153). However, it was recently shown that Cerk activity is much more
dependent on Mg2+ than Ca2+ (155).
Two sites in hCerk have been found to be consistently phosphorylated – serines 340 and
408 – though the functional consequence of these phosphorylation events is unclear, as point
mutations did not lead to changes in subcellular localization or activity (154). The S340A mutant
did, however, have decreased stability (154). The serine 340 site is a putative casein kinase II
phosphorylation site (147), while the serine 408 site is a putative ERK or CDK phosphorylation
site (146).
Based on homology of Cerk’s kinase domain with DAGK’s kinase domain, the glycine 198
residue was found to coordinate ATP (156). The glycine residue in DAGK’s kinase domain is
known to be essential for catalytic activity, and mutation of glycine 198 to aspartate in Cerk was
able to generate a kinase dead mutant (156).
While much work remains to be done in characterizing the regulation of Cerk at the
levels of transcription, translation, or post-translational modifications, one group did find by
chromatin immunoprecipitation in keratinocytes that PPARβ binds the Cerk gene at a sequence
located in first intron, leading to Cerk up-regulation and increased cell survival (157). Another
group found a CREB binding site in Cerk’s promoter region and demonstrated that Cerk is upregulated in response to CREB phosphorylation (158).
Cerk’s only known function is to phosphorylate ceramide at the C-1 position to generate
ceramide-1-phosphate (C1P), with no production of the C-3 product (159). Although it has high
homology to DAGK and SphK, Cerk has no activity against DAG or sphingosine (147). Cerk
requires its substrate to have a minimum of 12-carbons in its acyl chain, and is stereospecific for
naturally occurring D-erythro-ceramides (159). To date, it is unclear how C1P is
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dephosphorylated, as no phosphatase has been identified, but C1P phosphatase activity has
been reported in plasma membrane fractions of mouse liver and brain (160–162).
Cerk is localized mostly to the trans-Golgi, but can also be found at the plasma
membrane and in cytoplasmic vesicles (146). Cerk preferentially uses ceramide provided by
CERT rather than by vesicular transport from the endoplasmic reticulum to the Golgi (163),
which agrees with the observation that the major subspecies of C1P are C16:0, C18:0 and C20:0
(163), the subspecies specifically transported by CERT (164). However, conflicting results show
CERT knockdown does not affect C1P production (165), which may indicate the ability of Cerk to
also use ceramide trafficked by vesicular transport.
Cerk kinase activity is measurable in all mouse tissues, but is especially high in the testis,
cerebellum, pancreas, and cerebrum. Northern analysis shows high Cerk mRNA expression in
the mouse testis, heart and spleen, demonstrating a lack of correlation between mRNA and
measurable kinase activity levels (155).
Cerk knockout mice have been generated independently by two laboratories, both by
homologous recombination in ES cells. The Igarashi group generated a knockout in the C57BL/6J
background (166). They found those mice to be healthy and fertile, with no histological
abnormalities. They did find changes in ambulation and defecation patterns due to abnormal
emotional behavior associated with low C1P in Purkinje cells. However, surprisingly, they found
C1P levels were not significantly different between Cerk+/+ and Cerk-/- mice in most tissues,
which may explain the very mild phenotypes observed.
The Bornancin Group generated their knockout mouse in the BALB/c background (167).
This group saw a profound reduction in levels of C1P formed in macrophages, although they did
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see significant residual C1P levels. The major phenotype observed was neutropenia, which was
associated with significantly increased levels of ceramide in the serum of these animals.
Each of these groups observed significant residual levels of C1P in Cerk-/- mice. This
implies that another mechanism must exist to generate C1P in the absence of Cerk. Conflicting
results exist about the existence of a Multi-Substrate Lipid Kinase (MuLK) (168), now known as
Acylglycerol Kinase (AGK) (155) (accession numbers AJ278150 and AJ401619). There is a single
report that recombinant MuLK may have activity toward ceramide, diacylglycerol and 1acylglycerol, but not sphingosine (168), though this has not been confirmed since the initial
report.

Ceramide-1-Phosphate
All of the functions attributed to Cerk are believed to be carried out by its product, C1P.
Soon after its discovery, C1P was shown to be mitogenic for fibroblasts, able to block apoptosis
in macrophages, control phagocytosis in neutrophils, and mediate inflammatory responses
(169). Many studies have characterized the effect of C1P on signaling by using exogenous shortchain C1P, as long-chain C1Ps are extremely hydrophobic and cannot cross the plasma
membrane. This has drawn criticism due to the non-physiological chain lengths of C1Ps utilized
and their presence in extracellular space. C1P is not known to be secreted and no cell surface
receptors have been identified to date. Keeping in mind those caveats, exogenous short chain
C1P was shown to stimulate DNA synthesis and promote cell division in rat fibroblasts (170).
Moreover, exogenous C1P was able to prevent apoptosis induced by macrophage-colony
stimulating factor (M-CSF) withdrawal in bone marrow-derived macrophages (171), withdrawal
of which is known to induce widespread apoptosis in these cells. C1P blocked DNA
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fragmentation and stimulation the of caspase-9 and caspase-3 pathway, inhibiting apoptosis
(171). C1P can also bind to and inhibit A-SMase directly – demonstrated by its inhibition of ASMase in cell homogenates –, preventing accumulation of ceramide (171), thus amplifying its
anti-apoptotic effects.
The first bona fide target of C1P to be described was cPLA2. C1P was shown to directly
bind to and activate cPLA2 through its C2/CaLB domain at the plasma membrane (172). C1P
specifically activates cPLA2 by an allosteric mechanism, and additionally lowers its dissociation
constant from phosphatidylcholine-rich vesicles (172,173). The cPLA2-COX-2 pathway is often
activated in inflammation and cancer pathogenesis (53,174), so Cerk has become of interest as a
drug target for both of those pathologies (Figure 1.2).
C1P is also a potent inhibitor of PP1 and PP2A in vitro (173), consistent with its
mitogenic effects. The potential of C1P to exert anti-apoptotic effects by inhibiting PP1 activity
may be due to SR proteins, which are well-characterized PP1 targets. SR proteins, named after
their characteristic serine- and arginine-rich domains, are involved in alternative mRNA splicing
and have known roles in cancer, including pro-apoptotic changes in splicing of caspase-9 and
Bcl-x pre-mRNA (173,175). In addition to its allosteric activation of cPLA2, C1P-mediated
inhibition of PP1 and PP2A may prevent dephosphorylation of cPLA2 at serines 505 and 727
(173). Phosphorylation of both of these residues, mediated by the MAPK pathway, is required
for arachidonic acid release from the membrane (176).
Since the discovery that C1P can inhibit apoptosis in many contexts, it has been
implicated in a variety of mitogenic signaling pathways. Importantly, C1P has been
demonstrated to stimulate PI3K/AKT signaling in macrophages and in A549 lung
adenocarcinoma cells, leading to NF-κB signaling and Bcl-xL up-regulation (177–183). The mTOR
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/ S6 kinase pathway was shown to play a role downstream of PI3K/AKT signaling stimulated by
C1P in bone marrow-derived macrophages (183). There have, however, been conflicting reports
on whether C1P can activate or suppress MAPK signaling (170,178,179,182–184), implying this is
most likely cell type and context specific.
Subcellular localization of C1P may be important to its ability to activate specific
signaling pathways. Ceramide-1-Phosphate Transport Protein (CPTP), or GLTPD1, traffics C1P
between the trans-Golgi and the plasma membrane. Decreased CPTP trafficking leads to C1Pmediated activation of cPLA2 in the Golgi, arachidonic acid release, and eicosanoid synthesis
(185).
Due to the increasing evidence that C1P (and thus Cerk) is implicated in inflammation,
cell survival, and evasion of apoptosis, inhibitors of Cerk have been under development. NVP231 is a diamino-benzothiazole derivative, active against Cerk in the low nanomolar range. It
was identified through the screening of over a million compounds (186). NVP-231 is a reversible
inhibitor of Cerk competitive toward the ceramide substrate (Ki = 7.4 nM). It demonstrated no
inhibition of SphK, DAGK or CERT. NVP-231 inhibits Cerk-dependent C1P formation but has no
effect on proliferation and does not lead to induction of cell death. NVP-231 in combination
with tamoxifen led to increased ceramide levels and reduced cell growth (186). Unfortunately,
due to poor bioavailability and rapid clearance in vivo (186) it has no potential for clinical
development, but could be a useful tool for in vitro investigation.
Another inhibitor of Cerk is called K1. It was initially proposed to be a tetrasubstituted
olefin isomer of the naturally occurring sphingosine kinase inhibitor F-12509A (187), but its
structure was later revised to a dihydropyrane cyclization product of F-12509A (188). It is a noncompetitive inhibitor of Cerk, with no effect on SphK or DAGK. It was shown in culture to
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suppress mast cell degranulation and was not cytotoxic. Its Ki was 2.2 µM, and its IC50 was
approximately 200 µM (189). This inhibitor has never been tested in animals so it is not known
whether it has potential for clinical development.

Cerk and C1P in Cancer
Increasing lines of evidence have implicated both Cerk and its product C1P in cancer.
High CERK expression has been reported to be associated with poor recurrence-free survival in
women with ER-negative breast cancer (190). CERK expression was also shown to be associated
with aggressive subtypes of breast cancer, including ER-negative status, HER2-positive status,
and high tumor grade (190).
Lung tumor removal in non-small cell lung cancer (NSCLC) patients leads to significant
down-regulation of several enzymes associated with ceramide metabolism in peripheral blood
mononuclear cells, including Cerk (specifically in NK cells and T cells), S1P receptor 5 (S1PR5) and
N-SMase 2, indicating that these enzymes may serve as biomarkers for lung cancer diagnosis
(191). Furthermore, a retrospective analysis of five clinical trials was used to develop an RNAi
screen-derived mitotic and ceramide pathway metagene that predicted response to adjuvant
paclitaxel in triple negative breast cancer (192). The fact that enzymes involved in ceramide
metabolism were found to predict paclitaxel sensitivity is consistent with previously presented
evidence that overexpression of GCS promotes resistance to paclitaxel and GCS inhibition
promotes paclitaxel sensitivity (192).
Some evidence from cancer cell lines has also help confirm the role of Cerk in cancer.
For example, Cerk was found to be up-regulated in the hormetic response of hepatoma cells to
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low dose UV irradiation, and Cerk knockdown increased the susceptibility of these cells to UVinduced apoptosis (193).
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Thesis Objectives
Although ceramide and its metabolites have been demonstrated to play important roles
in cell death following therapy in vitro, whether this pathway plays a functional role in tumor
progression or tumor recurrence has not been addressed. Moreover, despite being
cytoprotective in tumor cell lines in vitro and predicting poor recurrence-free survival in ERnegative breast cancer patients, a functional role for Cerk and C1P has not been established in
tumorigenesis or tumor recurrence. The goal of this thesis was to try to define a functional role
for Cerk in tumor progression through the following specific aims:

1a. To test the effect of overexpressing Cerk on mammary tumor progression
As Cerk had previously been shown to be cytoprotective in the context of many cellular
stresses, we hypothesized that Cerk might play a role in tumor cell survival following oncogene
down-regulation. To test this hypothesis, we first sought to characterize Cerk expression
throughout tumor progression in inducible oncogene-driven mammary tumor mouse models.
We then used Cerk overexpression in HER2/neu-driven mouse tumor cells to perform gain-offunction experiments in vitro and in vivo, assessing specifically the ability of enforced Cerk
expression to protect cells and tumors from apoptosis. We also sought to test whether Cerk was
sufficient to promote tumor recurrence in an in vivo recurrence assay.

1b. To determine whether CERK is a prognostic indicator in breast cancer patients
Additionally, we interrogated human breast cancer patient datasets to determine
whether CERK expression was predictive of outcome. Furthermore, we asked if high CERK
expression was associated with other prognostic factors, such as ER status, PR status, HER2
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status, tumor grade, lymph node status and tumor size. We also asked whether the association
between CERK expression and relapse-free survival in breast cancer patients was independent
of the association between CERK expression and these aggressive tumor subsets.

2. To test the effect of Cerk knockdown on mammary tumor progression
To complement Cerk gain-of-function experiments, we wanted to test the requirement
for Cerk in tumor cell survival and tumor recurrence. We therefore performed loss-of-function
experiments using two targeting short hairpin RNAs against Cerk. We also utilized the small
molecule inhibitor of Cerk NVP-231 to try to inhibit Cerk in vitro.
Due to difficulty maintaining Cerk knockdown in vivo, we sought to generate a
conditional shRNA expression system that could be expressed at specific timepoints throughout
tumor progression. Although this system was not optimized sufficiently to provide evidence of
Cerk’s requirement for tumor recurrence, future studies will focus on optimizing this system to
answer these questions.

Additionally, future studies will need to identify specific signaling pathways that may be
involved in mediating the effect of Cerk on tumor cell survival and tumor recurrence. Also,
confirming whether the effects of Cerk are in fact mediated by C1P will be of utmost
importance, and changes in C1P levels following manipulation of Cerk expression will be
indicative of whether C1P is mediating the effects of Cerk.
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Figure 1.1: Ceramide synthetic and metabolic pathways

Adapted from Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis
and treatment. Nat Rev Cancer. 2004;4:604–16.
Summary of de novo synthesis of ceramide as well as major ceramide metabolic pathways.
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Figure 1.2: C1P activates cPLA2 leading to eicosanoid synthesis and tumor-promoting signaling

Based on and adapted from Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer.
2010;10:181–93.
C1P generated by Cerk activates cPLA2 at the plasma and Golgi membranes, leading to cleavage
of arachidonic acid from membrane phospholipids. Arachidonic acid is then converted into a
variety of eicosanoids, including prostaglandins, specifically PGE2. PGE2 is known to be protumorigenic and activate EP1-4 receptors in an autocrine and paracrine manner, leading to
mitogenic signaling through pathways including Ras and inhibition of GSK3β.
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Figure 1.3. Ceramide and ceramide-1-phosphate signaling pathways

Overview of signaling pathways downstream of ceramide and ceramide-1-phosphate. Ceramide
signals through many pro-apoptotic pathways, including SAPKs and the phosphatases PP1 and
PP2A. By contributing to cell cycle arrest, protein synthesis arrest, and mitochondrial
permeability, ceramide promotes apoptosis. In contrast, ceramide-1-phosphate signals through
several pro-survival and inflammatory pathways including PI3K/AKT and cPLA2, which is the ratelimiting step in eicosanoid synthesis.
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CHAPTER 2: Gain-of-Function Cerk Experiments
Introduction
C1P and its synthetic enzyme Ceramide Kinase (Cerk) have been implicated in a number
of pro-tumorigenic cellular processes, including inflammation, proliferation and cell survival.
Several studies have shown that Cerk is cytoprotective in many contexts by generating C1P,
which signals through the PI3K/AKT pathway (177,180,194). C1P has also been reported to
activate cPLA2, recruiting it to Golgi and plasma membranes, resulting in the cleavage of
arachidonic acid that is then converted into a variety of eicosanoids, including prostaglandins.
Prostaglandins have, in turn, been associated with many inflammatory processes as well as
regulation of cell growth (195) and cancer (reviewed in (196)). High CERK expression has been
reported to be associated with poor recurrence-free survival in women with ER-negative breast
cancer (190). CERK expression has also shown to be associated with aggressive subtypes of
breast cancer, including ER-negative status, HER2-positive status, and high tumor grade (190).
Although ceramide and its metabolites have been demonstrated to contribute to cell
death following therapy in vitro, whether this pathway plays a functional role in tumor
progression in vivo has not been addressed. Moreover, despite being cytoprotective in tumor
cell lines in vitro and predicting poor recurrence-free survival in ER-negative breast cancer
patients, functional roles for Cerk and C1P have not been established in tumorigenesis or tumor
recurrence.
In this study, we identify a functional role for Cerk in breast cancer recurrence. We
demonstrate that Cerk is spontaneously up-regulated during tumor recurrence in mice and is
rapidly up-regulated in response to HER2/neu pathway inhibition or treatment with adriamycin.
We further establish that Cerk promotes tumor cell survival following HER2/neu down33

regulation and is sufficient to promote mammary tumor recurrence. Consistent with
observations in mice and with an analogous role for this enzyme in human breast cancer, we
find that elevated CERK expression in primary tumors is strongly associated with an increased
risk of relapse in breast cancer patients. Taken together, these observations provide the first
functional evidence for a role for Cerk in cancer and identify a potential target for the treatment
and prevention of breast cancer recurrence.
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Results
Cerk is spontaneously up-regulated in recurrent mammary tumors in mice
As an initial approach to investigating the potential role of sphingolipid metabolites in
tumor progression, we evaluated the expression of enzymes involved in sphingolipid
metabolism in primary and recurrent mammary tumors induced by the inducible expression –
and subsequent down-regulation – of HER2/neu, c-MYC, Wnt1, and Akt1 in MMTV-rtTA;TetOHER2/neu, MMTV-rtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1
transgenic mice (45–49). Expression of sphingosine kinase 1, which generates S1P from
sphingosine, and glucosylceramide synthase, which generates glucosylceramide from ceramide,
were not consistently altered in recurrent compared to primary tumors (data not shown). In
contrast, expression of Cerk, which generates C1P from ceramide, was markedly up-regulated in
recurrent tumors compared to primary tumors generated by induction of each of the four
oncogenes tested (Figure 2.1A).

Cerk is up-regulated following HER2/neu pathway inhibition
To identify the stage of tumor progression at which Cerk up-regulation occurs, tumors
were harvested from doxycycline-induced MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice bearing
primary tumors, MTB/TAN mice bearing primary tumors in which the HER2/neu transgene had
been de-induced for 48 hr or 96 hr, or MTB/TAN mice bearing primary tumors that had fully
regressed and then spontaneously recurred following doxycycline withdrawal and HER2/neu
down-regulation.
Quantitative RT-PCR analysis demonstrated Cerk up-regulation in mammary tumors
within 48 hr following doxycycline withdrawal, which reached statistical significance by 96 hr
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and remained up-regulated 4.1-fold in recurrent tumors (Figure 2.1B). To determine whether
alterations in Cerk expression occur in tumor cells subjected to HER2/neu down-regulation, we
next evaluated Cerk mRNA levels following oncogene down-regulation in vitro in doxycyclinedependent primary tumor cells derived from a tumor-bearing MTB/TAN mouse. Doxycycline
withdrawal resulted in Cerk up-regulation within 24 hr that became somewhat more
pronounced over time (Figure 2.1C). This finding suggests that Cerk may be acutely up-regulated
in primary tumor cells in response to HER2/neu pathway down-regulation.
To determine whether CERK up-regulation is an evolutionarily conserved response to
HER2/neu pathway inhibition in breast cancer cells, we treated two HER2/neu-amplified human
breast cancer cell lines, BT474 and SKBR3, with the dual inhibitor of HER2/neu and EGFR,
lapatinib. Treatment with lapatinib resulted in up-regulation of CERK in each of the HER2/neu
amplified cell lines relative to controls within 24 hr (Figure 2.1D, E), demonstrating that CERK upregulation is conserved in human and mouse breast cancer cells following HER2/neu pathway
inhibition.
To determine whether CERK up-regulation is also seen in response to other types of
anti-neoplastic therapy, we treated BT20 human breast cancer cells with the chemotherapeutic
agent adriamycin for increasing periods of time. Adriamycin treatment resulted in marked upregulation of CERK within 8 hr, peaking at 6.5-fold at 24 hr relative to vehicle-treated controls
(Figure 2.1F). Consistent with this, CERK was up-regulated within 4 hr in primary MTB/TAN
mouse tumor cells treated with adriamycin, with levels peaking at 4.5-fold at 16 hr (Figure 2.1G).
Together, these data indicate that CERK is rapidly up-regulated in mouse and human mammary
tumor cells following HER2/neu pathway inhibition or treatment with adriamycin.
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Cerk promotes tumor cell survival in vitro following HER2/neu down-regulation
Having observed acute Cerk up-regulation following HER2/neu pathway inhibition in
vivo and in vitro, we hypothesized that Cerk up-regulation might contribute to the survival of
tumor cells following HER2/neu pathway inhibition. Doxycycline was removed from the culture
media of primary MTB/TAN tumor cell lines transduced with expression constructs for wild type
Cerk or the kinase dead mutant G198D-Cerk, which are expressed at comparable levels (data not
shown), or a control vector. Cells were then stained for cleaved caspase-3 and Ki67.
Cerk overexpressing MTB/TAN cells exhibited markedly reduced staining for cleaved
caspase-3 compared to control cells following HER2/neu down-regulation induced by
doxycycline withdrawal (Figure 2.2A, B). In contrast, MTB/TAN cells transduced with kinase dead
G198D-Cerk exhibited an increase in cleaved caspase-3 staining following HER2/neu downregulation that was comparable to control cells (Figure 2.2A, B). As anticipated, proliferation
rates as measured by Ki67 staining fell dramatically upon HER2/neu down-regulation, but did
not differ between Cerk, G198D-Cerk, and empty vector controls (Figure 2.2C). These findings
suggest that Cerk overexpression is sufficient to suppress apoptosis induced by HER2/neu
pathway inhibition and that it does so in a kinase-dependent manner.
To confirm the increase in apoptosis observed by immunofluorescence, we performed
Western blots for cleaved caspase-3 and cleaved PARP under the same culture conditions.
Consistent with immunofluorescence results, Cerk overexpression reduced levels of cleaved
PARP and cleaved caspase-3 detected following doxycycline withdrawal (Figure 2.2D, E, F).
Kinase dead G198D-Cerk had comparable levels of cleaved PARP and cleaved caspase-3 as
controls, indicating that kinase activity is required for Cerk to protect cells from apoptosis.
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Cerk promotes tumor cell survival in vivo following HER2/neu down-regulation
Having observed a protective effect of Cerk overexpression in MTB/TAN cells in vitro
upon HER2/neu down-regulation, we wanted to determine whether this would occur in vivo. To
address this possibility, we generated mice bearing orthotopic tumors derived from MTB/TAN
primary tumor cells overexpressing wild type Cerk, kinase dead G198D-Cerk, or a control vector.
We then performed immunofluorescence staining for cleaved caspase-3 on histological sections
from primary tumors on doxycycline or in which HER2/neu had been acutely down-regulated for
48 or 96 hr.
Primary tumors from control, Cerk and G198D-Cerk overexpressing cohorts exhibited
comparable, low levels of cleaved caspase-3 staining in the presence of HER2/neu expression
and a marked increase in cleaved caspase-3 staining was observed 48 hr following doxycycline
withdrawal (Figure 2.3A, B). Strikingly, however, tumors overexpressing Cerk displayed a
significantly blunted apoptotic response to HER2/neu down-regulation at 48 hr postdeinduction, and cleaved caspase-3 levels remained lower in Cerk overexpressing tumors
compared to controls at 96 hr (Figure 2.3A, B). In contrast, tumors overexpressing the kinase
dead mutant G198D-Cerk did not blunt the apoptotic response and exhibited high levels of
cleaved caspase-3 comparable to control tumors following HER2/neu down-regulation (Figure
2.3A, B). These findings indicate that Cerk up-regulation protects tumor cells from apoptosis
following HER2/neu pathway inhibition, suggesting a cellular mechanism for the observation
that cells with Cerk knockdown are selected against following oncogene down-regulation in vivo.
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Cerk promotes mammary tumor recurrence in vivo
Cerk’s ability to inhibit apoptosis following HER2/neu down-regulation in tumor cells in
vivo and in vitro, coupled with its spontaneous up-regulation in recurrent mammary tumors in
multiple genetically engineered mouse models, suggested the possibility that Cerk might
promote breast cancer recurrence by enhancing the survival of tumor cells following therapy. To
test this hypothesis, we injected primary MTB/TAN tumor cells transduced with a Cerk
expression vector or a control vector into the mammary fat pads of nu/nu mice maintained on
doxycycline. Following primary tumor formation, mice were withdrawn from doxycycline to
induce oncogene down-regulation and tumor regression (Figure 2.4A). All tumors regressed to a
non-palpable state, irrespective of Cerk expression status. Mice were then monitored for tumor
recurrence.
Consistent with our hypothesis, Cerk expression in MTB/TAN tumor cells markedly
accelerated tumor recurrence, with median time to recurrence decreasing from 178 days for
control tumors to 130 days in Cerk overexpressing tumors (Figure 2.4B, HR = 4.44, p = 0.0006).
However, mean growth rate of recurrent tumors was not found to be different between control
and Cerk overexpressing cohorts, indicating increased rates of proliferation are unlikely to be
responsible for the observed difference in latency to tumor recurrence (Figure 2.4C).
The above experiment could not rule out the possibility that the increased rate of
relapse observed for Cerk overexpressing tumors was due to effects of Cerk expression during
primary tumor formation. That is, if Cerk expression resulted in the formation of primary tumors
with different properties than control tumors, this could explain the reduced time to recurrence,
rather than effects of Cerk following HER2/neu down-regulation. To address the potential
confounding effects of Cerk expression during primary tumor formation, we modified the
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orthotopic recurrence assay to eliminate primary tumor formation, thereby isolating the effects
of Cerk on tumor cell survival and recurrence.
Recipient mice pretreated with doxycycline were injected with control or Cerk
overexpressing cells and then withdrawn from doxycycline after 48 hr, before primary tumors
had formed (Figure 2.4D). Consistent with our prior results, Cerk overexpression accelerated the
rate of mammary tumor recurrence and reduced the median time to recurrence from 304 days
in controls to 185 days in the presence of Cerk expression (Figure 2.4E, HR = 3.64, p = 0.002).
Again, mean growth rate was not found to be different between control and Cerk
overexpressing cohorts (Figure 2.4F). These results indicate that Cerk can promote mammary
tumor recurrence following HER2/neu down-regulation and that this effect is unlikely to be due
to Cerk-induced alterations in primary tumor formation.

Elevated CERK expression is associated with an increased risk of recurrence in women with
breast cancer
A prior report suggested that elevated CERK expression is associated with poor
prognosis in ER-negative breast cancer patients (190). To confirm and extend this analysis, we
interrogated publicly available human breast cancer expression datasets corresponding to 2,224
patients with tumors of mixed ER status in order to evaluate the association of CERK expression
with recurrence-free survival in a meta-analysis. Using a Cox proportional hazards (PH) model,
we found that women with primary tumors expressing high levels of CERK exhibited an
increased risk of tumor recurrence within five years of diagnosis (Figure 2.5, HR = 1.32 [1.17 –
1.49]).
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We next asked whether CERK expression is associated with aggressive subtypes of
breast cancer. Association studies revealed that CERK is expressed at higher levels in ERnegative compared to ER-positive, and PR-negative compared to PR-positive, tumors. CERK
expression was also associated with HER2-positive status as assessed by immunohistochemistry
(Figure 2.6A-C). Evaluation of CERK expression as a function of molecular subtype revealed that
CERK expression is higher in the basal and ErbB2 subtypes compared to the luminal A and
luminal B subtypes (Figure 2.6D). CERK expression was also associated with high tumor grade
(Figure 2.6E), but not with tumor size or lymph node status (data not shown).
Since ER-negative, PR-negative, HER2-positive, basal-like and high grade tumors are
each associated with a poor prognosis, we wished to determine whether the association
between CERK expression and relapse-free survival in breast cancer patients was independent
of the association between CERK expression and these aggressive tumor subsets. To address
this, we performed multivariate Cox proportional hazards regression in combination with metaanalyses and adjusted for each of these variables individually. In each case, we found that the
association between elevated CERK expression and decreased recurrence-free survival remained
significant after adjusting for ER status, PR status, HER2 status, molecular subtype or tumor
grade (Figure 2.7A–E). Influence analysis performed on each significant result obtained by metaanalysis confirmed that these results were independent of any single dataset (Figure 2.8).
In aggregate, our results indicate that CERK expression in human breast cancer is
associated with an increased risk of recurrence within five years, and is independent of the
association between CERK expression and aggressive subtypes of human breast cancer.
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Discussion
The importance of ceramide metabolism in cancer has become of increasing interest in
recent years (53,107,197). However, relatively little functional data have emerged in describing
ceramide, its metabolites and the metabolic enzymes responsible for their generation in
tumorigenesis and tumor progression.
In a number of tumor cell lines, Cerk has been reported to exert cytoprotective effects
in a variety of in vitro contexts, including serum starvation, TNFα signaling and UV irradiation. To
date, however, no evidence has existed for a functional role for Cerk in tumor cell survival in
vivo, tumor progression or tumor recurrence. Using genetically engineered mouse models,
human breast cancer cell lines and expression data from breast cancer patients, we have now
identified a functional role for Cerk as a regulator of tumor cell survival and breast cancer
recurrence following HER2/neu down-regulation.
We found that Cerk is spontaneously up-regulated during the process of tumor
recurrence in mammary tumors driven by four different oncogenic pathways. Notably, Cerk was
up-regulated as early as 96 hr following oncogene down-regulation in mice bearing HER2/neudriven mammary tumors and, consistent with this, human HER2/neu-amplified breast cancer
cell lines also rapidly up-regulated Cerk following HER2/neu pathway inhibition. Indicative of a
role for Cerk in the context of HER2/neu inhibition, enforced Cerk expression inhibited
apoptosis.
In accord with the anti-apoptotic effects of Cerk in tumor cells following HER2/neu
down-regulation, Cerk expression in orthotopic primary mammary tumor cells promoted tumor
recurrence, indicating a functional role for Cerk in this stage of tumor progression. In aggregate,
our findings indicate that Cerk is required for tumor cell survival following HER2/neu down42

regulation. Ostensibly, this may result in a larger pool of surviving residual tumor cells that can
potentially give rise to recurrent tumors. These findings therefore suggest a therapeutic
opportunity whereby inhibition of Cerk in concert with treatment with targeted therapies may
enhance tumor cell death, reduce the reservoir of residual tumor cells, and thereby prevent
tumor recurrence.
In agreement with its functional role in mammary tumor recurrence elucidated in mice,
CERK was associated with increased risk of recurrence in human breast cancer patients. CERK
expression was associated with aggressive subtypes of breast cancer, including ER-negative, PRnegative, HER2-positive, high grade, and ErbB2 and basal-like tumors. However, the association
between CERK and relapse-free survival was independent of its association with these
aggressive subsets of tumors. As such, while CERK was previously reported to be associated with
decreased recurrence-free survival in ER-negative breast cancer patients (190), our findings
extend this analysis by demonstrating that CERK is associated with poor outcome in all breast
cancer patients and does so independently of its association with individual aggressive
prognostic factors.
In aggregate, our findings may identify Cerk as a pathway for cell survival in breast
cancer cells, as well as define a subset of human breast cancers with a high likelihood of relapse.
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Materials and Methods
Animals and Orthotopic Recurrence Assays
All animal experiments were performed in accordance with guidelines of the
Institutional Animal Care and Use Committee at the University of Pennsylvania. MTB/TAN,
MTB/TOM, MTB/TWNT;p53+/- and MTB/TAKT mice were bred and tumors were generated as
previously described (45–48). Orthotopic recurrence assays and competition assays were
performed as described (49,198). Athymic (nu/nu) mice were obtained from Taconic
(Germantown, NY).

Tissue Culture and Reagents
Primary MTB/TAN tumor cells were cultured as described in the presence of doxycycline
(49,198). Primary tumor cells were transduced with retrovirally-packaged mCerk cDNA.
BT474, SKBR3 and BT20 cells were purchased from ATCC. All cells were cultured at 37°C
with 5% CO2. BT474 cells were cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS), 1% Penicillin/Streptomycin and 1% L-glutamine. SKBR3 cells were cultured
in McCoy’s 5A modified medium supplemented with 10% FBS, 1% Penicillin/Streptomycin and
1% L-glutamine. BT20 cells were cultured in EMEM medium supplemented with 10% FBS, 1%
Penicillin/Streptomycin and 1% L-glutamine.

Plasmids and RNAi
The cDNA for mCerk (MMM1013-202798251, Open Biosystems) was subcloned into the
pk1 vector as described (199). Mutation of the glycine residue at position 198 of human CERK to
aspartate was previously shown to generate a catalytically inactive Cerk mutant (156). After
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confirming this residue to be conserved in mouse, we generated the G198D mutant mCerk using
site-directed mutagenesis. Using the Quickchange Lightning Site-Directed Mutagenesis kit
(Agilent Technologies), we generated the primers G198D-F (forward, 5'CGTAGGTGGGGACGACATGTTCAGCGAGG-3') and G198D-R (reverse, 5'CCTCGCTGAACATGTCGTCCCCACCTACG-3'), and performed the mutagenesis reaction according
to manufacturer’s instructions.
cDNA plasmids were virally packaged using Plat-E cells (Morita et al., 2000), which were
transfected with retroviral constructs using Lipofectamine® 2000 (Life Technologies).
Supernatant containing viral particles was collected 48 hr post-transfection, filtered and used to
infect primary tumor cell lines. Transduction was performed in the presence of 4 µg/ml
polybrene (Millipore).

Antibodies
The following antibodies were used as indicated throughout the text: cleaved caspase-3
(Cell Signaling), cleaved PARP (Cell Signaling), Ki67 (Dako), β-Tubulin (Biogenex).

Immunoblotting
Protein lysates were generated by homogenizing cells in RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1% NP40, 0.5% NaDOC, 0.1% SDS) supplemented with HALTTM Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific).
Secondary antibodies conjugated to IRDye 800CW (LI-COR Biosciences) were used.
Odyssey V3.0 system (LI-COR Biosciences) was used to visualize and quantify proteins of
interest. Quantification was performed using ImageStudio software (LI-COR Biosciences).
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Immunofluorescence and Microscopy
For immunofluorescence studies of tumor tissue from the competition assay, tumors
were snap-frozen in OCT (TissueTek) and cut into 8 µm frozen sections. Sections were fixed in
4% PFA for 10 min then stained with Hoechst 33258 (Sigma). For cleaved caspase-3 staining,
tumors were fixed in 4% PFA in PBS overnight then embedded in paraffin. Sections were
prepared using a standard xylene-based de-waxing procedure, then subjected to antigen
retrieval and stained with appropriate primary and secondary antibodies.
For cell culture experiments, cells were seeded on 4-chamber slides, fixed in 4% PFA for
10 min then permeabilized with 0.5% Triton in PBS for 20 min. Slides were then stained with
corresponding primary and secondary antibodies. Fluorescence and immunofluorescence
microscopy were performed on a DM 5000B Automated Upright Microscope (Leica). Images
were captured with a DFC350 FX monochrome digital camera (Leica).

RNA Isolation and Quantitative RT-PCR
RNA was isolated from tumors using Trizol (Invitrogen) followed by RNeasy® RNA Mini
Kit (Qiagen). RNA was isolated from cells using the RNeasy® RNA Mini Kit (Qiagen). Reverse
transcription was performed using the High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems) according to manufacturer’s instructions. qPCR was performed on the ViiaTM 7 RealTime PCR System (Life Technologies) using 6-carboxyfluorescein-labeled Taqman probes for
mCerk, hCerk, mTBP and hTBP (Applied Biosystems). Relative expression levels were calculated
using the comparative CT method.
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Statistical Analyses
Unpaired Student’s t-tests were utilized to analyze normally distributed data. MannWhitney U tests were used when data were not normally distributed. Two-way ANOVAs were
used to compare paired data. Log-rank tests were used to analyze survival curves. p-values <
0.05 were considered statistically significant. Hazard ratios with 95% confidence intervals were
calculated for all survival curves.

Human Breast Cancer Microarray Data Analysis
We obtained publicly available microarray data and the corresponding clinical
annotations from 14 data sets encompassing 2,224 breast cancer patients (200–213).
Normalized data were downloaded from NCBI GEO or original authors’ websites. Microarray
data were converted to base-2 log scale where necessary. Affymetrix microarray data were renormalized using Robust Multi-array Average when .CEL files were available.
Association between Cerk mRNA expression and 5-year relapse-free survival was
estimated using meta-analysis of univariate Cox proportional hazards regression as previously
described (198). Meta-analyses were performed in subsets of patients stratified by ER status, PR
status, HER2 status, molecular subtype and tumor grade as described (198). Influence analyses
were performed on all significant findings derived by meta-analysis to determine whether the
significant result was independent of any single dataset.
The association between Cerk mRNA expression and known prognostic factors of human
breast cancer such as ER status, PR status, HER2 status, lymph node status, tumor size, tumor
grade and molecular subtype was assessed by ANOVA in pooled microarray datasets as
previously described (198).
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For each prognostic factor significantly associated with Cerk mRNA expression, we reassessed the association between Cerk mRNA expression and relapse-free survival after
adjusting for the prognostic factor in a multivariate Cox proportional hazards model. The
adjusted hazard ratios and confidence intervals for Cerk mRNA expression were aggregated
across multiple data sets and assigned an overall significance using meta-analysis as described
above.
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Figure 2.1: Cerk is spontaneously up-regulated in recurrent mammary tumors and following
acute HER2/neu inhibition
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(A) qRT-PCR analysis of Cerk mRNA expression in primary and recurrent HER2/neu, c-MYC, Wnt1,
and Akt1-driven tumors. (B) qRT-PCR analysis of Cerk mRNA expression from MTB/TAN tumors
at primary, 48 hr deinduced, 96 hr deinduced, and recurrent time points. (C) qRT-PCR analysis of
Cerk mRNA expression in primary MTB/TAN tumor cell line in vitro removed from doxycycline 1,
2, 4 or 6 days. (D) qRT-PCR analysis of CERK mRNA expression in BT474 cells and (E) SKBR3 cells
treated with 100 nM lapatinib or DMSO for 1, 2 or 3 days. qRT-PCR analysis of CERK mRNA
expression in (F) BT20 cells and (G) primary MTB/TAN cells treated with 10 µM adriamycin or
vehicle for 4, 8, 16 or 24 hr. *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.2. Cerk protects cells from apoptosis upon HER2/neu down-regulation in vitro

(A) Representative fluorescence images and (B) quantification of MTB/TAN primary tumor cell
lines expressing empty vector, Cerk or G198D-Cerk withdrawn from doxycycline 72 hr then
stained for cleaved caspase-3 (red; Hoechst = blue). (C) Quantification of MTB/TAN primary
tumor cell lines expressing empty vector, Cerk or G198D-Cerk withdrawn from doxycycline 72 hr
then stained for Ki67. (D) Western blot of MTB/TAN primary tumor cell lines expressing empty
vector, Cerk or G198D-Cerk withdrawn from doxycycline 48 hr, blotted for cleaved PARP,
quantified in (E), and cleaved caspase-3, quantified in (F). *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.3. Cerk promotes tumor cell survival in vivo following HER2/neu down-regulation

(A) Quantification of cleaved caspase-3 staining in primary orthotopic empty vector, Cerk and
G198D-Cerk tumors at 48 and 96 hr post-deinduction. (B) Representative fluorescence images of
primary tumors, 48 hr and 96 hr deinduced tumors stained for cleaved caspase-3 (red; Hoechst
= blue). *p<0.05, **p<0.01, ***p<0.001.
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Figure 2.4. Cerk promotes tumor recurrence in the MTB/TAN model.

(A) Schematic of recurrence assay and timing of doxycycline treatment. (B) Recurrence-free
survival of nude mice harboring primary orthotopic tumors from MTB/TAN primary cell lines
expressing empty vector or overexpression Cerk induced to regress by doxycycline withdrawal.
(C) Mean growth rate of control and Cerk overexpressing recurrent tumors. (D) Schematic of
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modified recurrence assay with no primary tumor formation. (E) Recurrence-free survival of
nude mice harboring MTB/TAN primary cell lines expressing empty vector or overexpressing
Cerk withdrawn from doxycycline 48 hr post-injection. (F) Mean growth rate of control and Cerk
overexpressing recurrent tumors.
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Figure 2.5. High CERK expression predicts decreased relapse-free survival in women with
breast cancer

Forest plot representation of 5-year survival estimates and hazard ratios for relapse-free survival
of individual datasets of human breast cancer patients.

55

Figure 2.6. CERK expression in human breast cancer subsets

Association between CERK mRNA expression and (A) ER status, (B) PR status, (C) HER2 status, (D)
molecular subtype and (E) tumor grade in pooled datasets of human breast cancer patients.
Each variable was analyzed by ANOVA.
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Figure 2.7. Multivariate analysis of the association of CERK expression and relapse-free
survival after adjusting for subsets
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Forest plot representation of 5-year survival estimates and hazard ratios after adjusting for the
impact of: (A) ER status, (B) PR status, (C) HER2 status, (D) molecular subtype and (E) tumor
grade. Multivariate analysis was performed to assess the hazard ratio (HR) in individual datasets.
Overall p-value and HR were calculated by meta-analysis.
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Figure 2.8. Influence analysis

Influence analyses were performed on all significant p-values derived by meta-analysis to
determine whether the significant result was independent of any single dataset.
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CHAPTER 3: Loss-of-Function Cerk Experiments
Introduction
In Chapter 2, we provided evidence that Cerk protects tumor cells from apoptosis upon
oncogene down-regulation and promotes mammary tumor recurrence. Cerk overexpression
inhibited apoptosis in MTB/TAN primary tumor cell lines in vitro and in orthotopic tumors in vivo
following HER2/neu down-regulation as indicated by decreases in cleaved caspase-3. This was
demonstrated to be dependent on Cerk’s kinase activity, as the kinase dead mutant G198D-Cerk
did not protect cells or tumors from apoptosis. Furthermore, Cerk overexpression markedly
accelerated tumor recurrence in an orthotopic model, illustrating its functional role in tumor
progression.
Having shown the relevance of Cerk in tumor cell survival and in mammary tumor
progression by gain-of-function experiments, loss-of-function experiments are crucial to
determine whether inhibition of Cerk would have therapeutic potential. Genetic experiments
knocking down Cerk are specific relative to pharmacological agents and important in
determining the effect of loss of Cerk. Also, two small molecule inhibitors of Cerk have been
developed, NVP-231 (186) and K1 (187,188), described in detail in Chapter 1. However, they
have not been thoroughly tested in vitro and have not been characterized at all in vivo, the
reason for which appears to be low bioavailability for NVP-231. In vivo studies with K1 have not
been published to date. Inhibitors with better pharmacokinetic profiles will likely need to be
developed in order to have potential use in vivo and in the clinic.
Mice lacking both alleles of Cerk are phenotypically normal, except for neutropenia
induced by apoptosis in granulocytes, which is associated with increased ceramide levels (167).
Tumor forming ability has not been assessed in these mice, however, endothelial cells derived
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from Cerk-/- mice display a VEGF-independent defect in angiogenesis (214). Cerk-/- mice have yet
to be tested in conjunction with oncogene-driven cancer models. This would provide very
specific answers as to the role of Cerk in tumorigenesis and tumor progression. For example,
crossing Cerk-/- mice with MMTV-rtTA;TetO-HER2/neu, MMTV-rtTA;TetO-MYC, MMTVrtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 transgenic mice would provide evidence for
the role of Cerk in tumorigenesis driven by specific oncogenes. Very few shRNA knockdown
experiments have been performed with Cerk, although some insight has been obtained from
Cerk-/- cells and treatment with NVP-231 or K1 in vitro (186,187,214).
Whether inhibition of Cerk with small molecules will be a successful approach in the
context of cancer remains to be elucidated. Some studies suggest that inhibition of Cerk activity
may not be sufficient to cause cell cycle arrest or death, but may sensitize cells to cytotoxic
agents (186), providing insight into potential for combination therapy.
In this chapter, we attempt to elucidate the effect of loss-of-function of Cerk and its
effect on tumor cell survival and mammary tumor recurrence. First, we generated Cerk
knockdown MTB/TAN primary tumor cell lines and tested them for sensitivity to apoptosis in the
context of HER2/neu down-regulation. We then tested these cell lines in vivo in orthotopic
recurrence assays and orthotopic cellular competition assays. Due to difficulty maintaining
shRNA knockdown of Cerk in in vivo experiments, we describe an attempt to characterize and
troubleshoot a conditional shRNA expression system in vitro and in vivo.
We obtained the Cerk inhibitor NVP-231 from Novartis to conduct pharmacological
studies on human breast cancer cell lines to determine whether inhibition of Cerk would
sensitize cells to apoptosis. These studies demonstrated that only at very high doses does NVP231 synergize with lapatinib to provide high levels of caspase activity indicating apoptosis. This is
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unlikely to be attributable solely to Cerk inhibition as the doses of inhibitor used were in the
millimolar range. To test the potential synergistic effect of Cerk inhibition with EGFR and
HER2/neu inhibition by lapatinib genetically, we knocked down CERK in BT474 cells treated with
lapatinib.
Lastly, having demonstrated a role for Cerk in cell survival acutely following HER2/neu
down-regulation, we wished to address the question of whether Cerk has a role in actively
proliferating primary and/or recurrent MTB/TAN tumor cell lines in an orthotopic setting in vivo.
We knocked down Cerk in one primary and two recurrent MTB/TAN tumor cell lines and
evaluated tumor growth in vivo. The results from these experiments leave many questions that
must be addressed to fully characterize Cerk’s potential as a drug target in cancer.
In aggregate, our findings about the difficulty in maintaining Cerk knockdown in
orthotopic recurrence assays in vivo may indicate a strong dependence of tumor cell lines on
Cerk signaling, which in turn may indicate that Cerk has potential as a drug target in cancer cells.
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Results
Cerk knockdown sensitizes tumor cells to apoptosis in vitro following HER2/neu downregulation
A previous report demonstrated that siRNA targeting Cerk sensitized A549 lung
adenocarcinoma cells to apoptosis following serum deprivation (178). To determine whether
loss of function of Cerk would sensitize cells to apoptosis following HER2/neu down-regulation,
we withdrew doxycycline from the culture media of primary MTB/TAN tumor cells expressing
either of two Cerk shRNAs, a scrambled control shRNA or an empty vector control. Cells were
then stained for cleaved caspase-3 and Ki67. Cerk knockdown cells exhibited markedly increased
staining for cleaved caspase-3 compared to control cells following doxycycline withdrawal
(Figure 3.1A, B). Proliferation rates fell dramatically upon HER2/neu down-regulation, but were
not significantly different between control and Cerk knockdown cells (Figure 3.1C). These
findings suggest that Cerk is required for the suppression of apoptosis following HER2/neu
down-regulation. Similarly, by Western blot, Cerk knockdown cell lines exhibited significantly
higher levels of cleaved PARP and cleaved caspase-3 than controls following doxycycline
withdrawal (Figure 3.1D-I).

Cerk is required for tumor cell survival following HER2/neu down-regulation in vivo
To expand our in vitro findings that Cerk protects tumor cells from apoptosis upon
HER2/neu pathway inhibition, we sought to test this in vivo. To determine whether Cerk is
required for the survival of tumor cells following acute HER2/neu down-regulation, we
performed an orthotopic fluorescent cell competition assay using an isogenic pair of
doxycycline-dependent MTB/TAN tumor cell lines that differed only in Cerk expression.
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MTB/TAN primary tumor cells expressing one of two shRNAs targeting Cerk were labeled with
an H2B-eGFP reporter, whereas MTB/TAN cells transduced with a control vector were labeled
with an H2B-mCherry reporter (Figure 3.2A). These two fluorescent populations of cells were
injected into the mammary glands of nu/nu mice at a 1:1 ratio and allowed to form orthotopic
primary tumors in the presence of doxycycline and HER2/neu expression. Doxycycline was then
withdrawn to initiate tumor regression and the ratio of eGFP-labeled Cerk knockdown cells to
mCherry-labeled control cells was determined in primary tumors, residual tumor cells 96 hr
following HER2/neu down-regulation, and residual tumor cells 28 days following HER2/neu
down-regulation by fluorescence microscopy performed on histological sections (Figure 3.1B).
Cerk shRNA-expressing cells were neither selected for nor against during the outgrowth
of primary orthotopic tumors (Figure 3.1C, D, F), indicating that Cerk knockdown does not confer
a selective advantage or disadvantage during primary tumorigenesis in the presence of
HER2/neu expression. In contrast, eGFP-labeled Cerk knockdown cells were strongly selected
against within 96 hr following doxycycline withdrawal and HER2/neu down-regulation, as these
cells comprised only 20-25% of the fluorescent tumor cells at this time point (Figure 3.1C, D, F).
By 28 days following doxycycline withdrawal, Cerk knockdown cells comprised only 14-20% of
fluorescent cells, indicating modest further negative selection against Cerk knockdown cells
(Figure 3.1C, D, F). Tumors containing control mCherry-labeled cells and control eGFP-labeled
cells maintained an approximately 1:1 ratio throughout tumor progression through all these
time points (Figure 3.1E). These findings indicate that cells in which Cerk has been knocked
down are rapidly and persistently selected against following HER2/neu down-regulation, but not
in actively growing primary tumor cells expressing HER2/neu.
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Cerk knockdown recurrence assays
Having observed strong selection against cells containing Cerk shRNAs in the context of
an orthotopic cellular competition assay, we sought to determine whether Cerk knockdown
would delay tumor recurrence. To determine whether Cerk is required for tumor recurrence, we
injected primary MTB/TAN tumor cells expressing either of two Cerk shRNAs, a scrambled
control shRNA or an empty vector control into the mammary fat pads of nu/nu mice maintained
on doxycycline. Analogous to experiments detailed in Figure 2.4A, following primary tumor
formation, mice were withdrawn from doxycycline to induce oncogene down-regulation and
tumor regression, then monitored for tumor recurrence.
Unexpectedly, although enforced expression of Cerk markedly accelerated tumor
recurrence (Figure 2.4B, E), Cerk knockdown cohorts did not display delayed tumor recurrence
as median time to recurrence did not differ significantly between any of the cohorts (Figure
3.3A). To investigate why Cerk knockdown did not alter the kinetics of recurrence, we harvested
primary tumors from these animals, extracted RNA and performed qRT-PCR to quantify Cerk
expression. Despite having seen greater than 65% knockdown in cell lines in vitro prior to
injection (Figure 3.2A), we did not observe any measurable knockdown in primary tumors
generated in mice injected with Cerk knockdown cells (Figure 3.3B). This may explain why no
effect was observed on latency to tumor recurrence. This suggests that Cerk knockdown may
not be compatible with tumor growth and must be circumvented for tumors to form.
In an attempt to isolate the effects of Cerk knockdown on tumor recurrence and avoid
the loss of knockdown occurring during the process of primary tumor formation, we used a
modified recurrence assay described in Figure 2.4D. Recipient mice pretreated with doxycycline
were injected with cells expressing either of two Cerk shRNAs, a scrambled control shRNA or an
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empty vector control and then withdrawn from doxycycline after 48 hr, before primary tumors
had formed.
Despite the modification of the recurrence assay to eliminate the potentially
confounding effects of primary tumor formation, we observed no effect on recurrence-free
survival between Cerk knockdown and control cohorts (Figure 3.3C). qRT-PCR analysis of
recurrent tumors from these animals showed no detectable Cerk knockdown (Figure 3.3D),
consistent with the loss of knockdown seen in the primary tumors of the original recurrence
assay (Figure 3.3B). This indicated that Cerk knockdown is not be sustained throughout tumor
recurrence, potentially due to selection against cells with high Cerk knockdown, to Cerk
upregulation, or to shRNA silencing. Therefore, to address whether Cerk was required for tumor
recurrence, a different approach became necessary.

FLIPi conditional shRNA expression system
We turned to the FLIPi conditional expression system developed by the laboratory of
Richard Hynes (215). This system allows for Cre-regulated expression of shRNAs, with a GFP
reporter prior to recombination and an mCherry reporter following recombination. We hoped
this system would permit controlled expression of shRNAs targeting Cerk at specific timepoints
throughout tumor progression, circumventing the loss of knockdown seen with a constitutive
shRNA expression system.
We first sought to confirm the ability of this vector to undergo Cre-mediated
recombination in vitro. As we received the FLIPi vector with a p53 shRNA (FLIPi-shp53), we
utilized this form of the vector for testing and transduced it into our primary MTB/TAN cell line.
Treatment with adenoviral (adeno)-Cre led to efficient recombination, as monitored by
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transition from GFP expression to mCherry expression and p53 knockdown detectable by qRTPCR (data not shown; performed by Lauren Pferdehirt).
To address the requirement for Cerk in tumor recurrence in vivo, this system required
adaptation, as no route of administration was known to efficiently deliver adeno-Cre to all cells
in a solid mammary tumor. Instead, a tamoxifen-inducible Cre-expressing MTB/TAN mouse cell
line would allow recipient mice to be treated with tumor-permeable tamoxifen by oral gavage in
order to induce recombination. To that end, we crossed bitransgenic MTB/TAN mice with UbcCreERT2 mice to generate triple-transgenic MTB/TAN;Ubc-CreERT2 offspring. At six weeks of age,
female MTB/TAN;Ubc-CreERT2 mice were administered doxycycline through drinking water to
induce tumor formation. Once tumors had formed, the animals were sacrificed, their tumors
excised, minced, then digested with collagenase, hyaluronidase, and trypsin. Tumor cells were
plated in culture to generate stable cell lines. Despite many attempts, only one stable cell line
was generated that was capable of continued passaging in vitro.

Testing of FLIPi in MTB/TAN;Ubc-CreERT2 cell line in vitro
MTB/TAN;Ubc-CreERT2 cells were transduced with the FLIPi-shp53 vector for testing of
recombination following tamoxifen treatment. Cells were selected with puromycin for one week
prior to testing. Puromycin was removed from the culture media prior to recombination testing,
as the puromycin resistance cassette is excised upon recombination (215). As tamoxifen is a prodrug that becomes hydroxylated by CYP450 enzymes in vivo, we utilized 4-OH-tamoxifen for in
vitro testing (216). Cells were treated with 100, 150, 200, 250 or 300 nM 4-OH-tamoxifen for 24
or 48 hr. The majority of untreated cells were GFP-positive and exhibited very rare spontaneous
recombination, monitored by mCherry expression, even when cultured in the absence of
67

puromycin for several passages (Figure 3.4A). Following 24 hr treatment with any dose of 4-OHtamoxifen, most cells still expressed GFP but also expressed mCherry (Figure 3.4A). By 48 hr
treatment, most cells expressed detectable mCherry and GFP expression was significantly
decreased (Figure 3.4B). GFP expression was no longer detectable at 96 hr at any dose of
treatment (data not shown). These results confirmed that this system is capable of tightly
controlled recombination induced by 4-OH-tamoxifen in vitro.

Characterizing MTB/TAN;Ubc-CreERT2 cell line in vivo
To test whether the MTB/TAN;Ubc-CreERT2 cell line could be used in vivo for orthotopic
recurrence assays, we sought to characterize its tumor forming ability, tumor morphology,
dependence on doxycycline, and ability to recur following oncogene-downregulation. We
injected the parental MTB/TAN;Ubc-CreERT2 cell line into the mammary fat pads of nu/nu mice
maintained on doxycycline. Following primary tumor formation, one cohort was sacrificed for
harvest of primary tumors. The remaining animals were withdrawn from doxycycline to induce
oncogene down-regulation and tumor regression. All tumors regressed to a non-palpable state.
Mice were then monitored for tumor recurrence.
Primary tumors exhibited a highly epithelial morphology (Figure 3.4C), with structures
mirroring the intact tumor from which this cell line originated. All animals withdrawn from
doxycycline displayed stochastic mammary recurrence with a median of 246 days. This confirms
that this MTB/TAN;Ubc-CreERT2 cell line is capable of primary tumor formation, is dependent on
doxycycline, forms epithelial tumors, and exhibits a highly penetrant recurrence phenotype.
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Testing of FLIPi recombination in MTB/TAN;Ubc-CreERT2 cell line in vivo
Having established the MTB/TAN;Ubc-CreERT2 cell line’s suitability for orthotopic
recurrence assays, we wished to determine whether the FLIPi vector could be recombined
efficiently in this cell line in vivo. We injected MTB/TAN;Ubc-CreERT2 cells transduced with FLIPishp53 into the mammary fat pads of nu/nu mice maintained on doxycycline. Primary tumors of
5 x 5 mm were allowed to form, animals were then treated with vehicle for 1, 3, or 5 days,
treated with tamoxifen 1, 3, or 5 days by oral gavage, or sacrificed. All treated animals were
sacrificed 72 hr after the final treatment to provide time for degradation of GFP and expression
of detectable levels of mCherry.
Tumors from untreated and vehicle treated animals were 100% GFP-positive at all
timepoints, with no detectable mCherry expression, indicating an absence of spontaneous
recombination (Figure 3.5A). Tumors from tamoxifen-treated animals underwent efficient
recombination at all timepoints, exhibiting strong mCherry expression (Figure 3.5B, C, D).
Residual GFP expression was detectable in tumors treated for one day (Figure 3.5B), but not in
tumors treated for 3 or 5 d. Therefore, the 3 d treatment course was chosen for further
experiments.

Recurrence assays with MTB/TAN;Ubc-CreERT2 cell line
Having identified an optimal treatment course for efficient recombination in vivo, we
sought to answer the question of whether Cerk is required for tumor recurrence. We set out to
test whether Cerk shRNA expression using this conditional system would have an effect on
latency of recurrence. We cloned two Cerk-targeting shRNAs as well as our scrambled control,
previously tested in the MLP vector, into the FLIPi vector. We also generated an empty vector by
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blunt-end ligation. These constructs were transduced into the MTB/TAN;Ubc-CreERT2 cell line,
then injected into the mammary fat pads of nu/nu mice maintained on doxycycline. Primary
tumors were allowed to form, then animals were treated by oral gavage for three consecutive
days with tamoxifen or vehicle. Mice were either sacrificed or removed from doxycycline on the
fourth day. All tumors regressed to a non-palpable state, regardless of Cerk knockdown status or
treatment regimen. Another cohort was sacrificed 96 hr post-deinduction. The remaining
animals were monitored for tumor recurrence.
Despite tightly-regulated and efficient recombination assessed by GFP or mCherry
fluorescence at sacrifice, the presence of Cerk shRNAs did not affect recurrence-free survival in
these animals. Median time to recurrence was not significantly altered in any of the cohorts,
whether treated with tamoxifen (Figure 3.6A) or with vehicle (Figure 3.6B). qRT-PCR analysis
revealed that Cerk expression in tumors arising from Cerk shRNA, scrambled or vector control
cells was not significantly different at any timepoint, and was not altered by treatment with
tamoxifen over vehicle (Figure 3.6C).

Troubleshooting FLIPi shRNA expression in vitro
Having observed no effect of FLIPi-shCerk recombination on tumor recurrence in the
orthotopic recurrence assay and no detectable Cerk knockdown in vivo at any timepoint, we
sought to determine whether Cerk was being effectively knocked down in this system in vitro.
Upon recombination, the FLIPi vector produces a single transcript with the mCherry reporter
followed by the shRNA. The transcript is then spliced at sites flanking the shRNA. Therefore, as a
surrogate for Cerk shRNA expression, we interrogated GFP and mCherry expression levels in
MTB/TAN;Ubc-CreERT2 cell lines with Cerk shRNAs compared to an empty vector control before
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and after 4-OH-tamoxifen treatment. In a different context, we had observed a bimodal
distribution of cells expressing low and high levels of fluorophores (data not shown, performed
by James Alvarez), which was hypothesized to correlate with levels of shRNA expression, which
may in turn lead to reduced knockdown detected globally. If true, this could provide an avenue
to allow us to sort for high levels of fluorophore expression to obtain higher levels of shRNA
expression and therefore better shRNA-mediated knockdown of Cerk. However, we did not
observe a bimodal distribution of fluorophore expression either before or after treatment with
4-OH-tamoxifen in vitro (Figure 3.7A), indicating that sorting out low-expressing cells is likely not
a solution to obtain better shRNA-mediated knockdown of Cerk.
As another method to potentially obtain better knockdown of Cerk with this system, we
transduced cells twice with the same vector. MTB/TAN;Ubc-CreERT2 cells were transduced with
each construct, selected with puromycin 72 hr post-transduction, grown for one week in the
presence of puromycin, then transduced again with the same construct. Total RNA was
extracted and qRT-PCR for Cerk expression was performed on cell lines following a single or
double infection. Cerk expression was compared to that of MTB/TAN cell lines expressing one of
two Cerk shRNAs, a scrambled hairpin or an empty vector control (MLPHG). Considerably less
knockdown was obtained with the same shRNAs targeting Cerk in FLIPi in MTB/TAN;Ubc-CreERT2
cell lines compared with MLPHG in MTB/TAN cells (Figure 3.7B). This does not explicitly address
whether this is the result of the cell line or the expression system. Double infection with FLIPi
vectors did not improve Cerk knockdown (Figure 3.7B).
To directly interrogate levels of shRNA expression, we designed miRNA primer-probe
sets against both Cerk-directed shRNAs to quantify expression of the shRNAs themselves. The
total RNA extracted from singly and doubly infected MTB/TAN;Ubc-CreERT2 cell lines was utilized
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for miRNA targeted RT and qPCR. Markedly lower levels of shRNA were expressed in FLIPi in
MTB/TAN;Ubc-CreERT2 cell lines than in MLPHG in MTB/TAN cell lines (Figure 3.7C, D). Double
infection appeared to moderately increase expression of Cerk shRNAs (Figure 3.7C, D), although
this did not lead to improved knockdown (Figure 3.7B). These results indicate that insufficient
shRNA expression may be the cause for undetectable levels of Cerk knockdown leading to
undetectable effects on tumor recurrence in the orthotopic setting. This system will have to be
optimized or altered to efficiently knock down Cerk and interrogate its role in tumor recurrence.

High dose NVP-231 treatment may synergize with lapatinib in HER2/neu–amplified human
breast cancer cells
To employ pharmacological methods to inhibit Cerk, we obtained the Cerk inhibitor
NVP-231 (Novartis) in order to assess whether pharmacological inhibition of Cerk would
sensitize human breast cancer cell lines to apoptosis. We treated BT474 and SKBR3 cells with
100 nM lapatinib or vehicle for 16, 24, or 48 hr along with increasing doses of NVP-231 from 100
nM to 3 µM and assessed apoptosis with the Caspase Glo® 3/7 Assay System (Promega). At
these points, 100 nM lapatinib did not lead to increases in luminescence, indicating that it did
not induce caspase-3 and caspase-7 cleavage (Figure 3.8A-F). NVP-231 alone did not lead to
significant increases in luminescence at any dose below 1 µM, and exhibited potentially
synergistic effects with lapatinib at 3 µM, particularly in BT474 cells at 16 hr and in SKBR3 cells
at 48 hr (Figure 3.8A, F).
These studies seem to indicate that only at high doses of NVP-231 does it synergize with
lapatinib to induce apoptosis, making it unlikely to be attributable solely to Cerk inhibition.
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Further examination of pharmacological inhibition of Cerk, possibly with other agents, will be
necessary to determine whether it is responsible for this effect.

Cerk may not be required for actively proliferating primary and recurrent tumors
We wanted to address the question of whether Cerk has a role in actively proliferating
primary and/or recurrent MTB/TAN tumor cell lines in an orthotopic setting in vivo. We injected
one primary and two recurrent MTB/TAN tumor cells expressing either of two Cerk shRNAs, a
scrambled control shRNA or an empty vector control (Figure 3.9A) into the mammary fat pads of
nu/nu mice maintained on doxycycline.
Cerk knockdown in primary and recurrent cell lines did not alter growth kinetics as
measured by tumor volume over time (Figure 3.9B, D, F) or as mean growth rate (Figure 3.9C, E,
G). This may indicate that Cerk is not required for actively proliferating primary or recurrent
tumors. However, this cannot distinguish between the possibility that Cerk knockdown may
have been selected against or otherwise lost in early stages of tumor growth, precluding the
appearance of a difference in tumor growth rate. This possibility cannot be eliminated as the
tumors were not tested for Cerk expression. Future studies will have to address this caveat.
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Discussion
The inhibition of ceramide metabolic pathways is under investigation in many cancers
and holds promise in clinical trials in combination with chemotherapy. Agents targeting
glucosylceramide synthase (GCS) and sphingosine kinase (SphK) have been tested in clinical
trials and hold promise as combination therapies in many cancers. Although Cerk has been
shown to regulate cell survival in the context of many stresses including chemotherapy,
radiotherapy and targeted therapy, the development and characterization of Cerk inhibitors is
lagging behind that of other enzymes involved in ceramide metabolism. Only two small
molecule inhibitors of Cerk have been identified to date. NVP-231 cannot be used in vivo due to
poor pharmacokinetics (186), while K1 has never been tested in animals. Much work remains to
be done to determine whether Cerk could be a successful drug target in human cancer patients.
We found that Cerk knockdown sensitizes tumor cells to apoptosis upon doxycycline
withdrawal and HER2/neu down-regulation in vitro. Furthermore, tumor cells in which Cerk had
been knocked down were strongly selected against within 96 hr following HER2/neu downregulation, with further selection continuing into the dormant phase of tumor regression at 28
days post-deinduction. Of note, we did not observe a selective effect against Cerk knockdown
cells in the primary tumor of the orthotopic competition assay, indicating that Cerk expression in
actively proliferating HER2/neu-driven tumor cells may not be rate limiting. This may also
indicate that a non-cell autonomous mechanism may be at play.
Based on published findings, we hypothesize that the paracrine secretion of PGE2 may
be responsible for maintaining Cerk knockdown cells in primary tumors in the competition assay
setting. Synthesis of C1P by Cerk is required for activation of cPLA2, which in turn releases
arachidonic acid from membrane phospholipids for the synthesis of eicosanoids including
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prostaglandins such as PGE2. PGE2 and other prostaglandins are then secreted and in an
autocrine and paracrine manner bind to and activate PGE2 G-protein coupled receptors, leading
to mitogenic signaling (Figure 1.2). This may allow Cerk knockdown cells to persist in primary
tumors in a setting where Cerk knockdown is usually lost (Figure 3.3B). This suggests that cellautonomous mechanisms become important upon HER2/neu down-regulation, as Cerk
knockdown cells were selected against very strongly within 96 hr despite the presence of control
cells.
The most abundant prostanoid in mammary tumors is PGE2, and high levels are
associated with poor prognosis (217). PGE2 is known to promote inflammation and be protumorigenic (218). The role of chronic inflammation in tumorigenesis is well-established, and
treatment with non-steroidal anti-inflammatory agents (NSAIDs) has been demonstrated to hold
promise as a chemopreventive approach to some human cancers, including the four most
prevalent cancers: breast, colon, lung and prostate (219–221). Cell-autonomous effects of
prostanoids, especially PGE2, have been implicated in the activation of pro-tumorigenic signaling
pathways, as exemplified by the stimulation of the Ras/Raf/MAP kinase and GSK3β – β catenin
pathways downstream of the EP (PGE2) receptors (222). Also, effects of prostanoids on the
mammary microenvironment, including stimulation of aromatase production in stromal fat cells,
have been shown to stimulate tumor cell proliferation (223). Lastly, secreted prostanoids may
have chemotactic functions for infiltrating neutrophils and macrophages that may have immune
suppressive functions in situ (224,225). As such, the potential involvement of Cerk and C1P in
eicosanoid-associated tumorigenesis would have important implications for the possible use of
anti-inflammatory drugs in chemoprevention.
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This also suggests that rate-limiting pathways regulating tumor cell growth and survival
may differ depending upon the stage of tumor progression. As such, pharmacological agents
that may be effective in treating primary breast cancers may have little effect in women with
minimal residual disease or recurrent breast cancer. As such, the identification of
pharmacological targets unique to these stages of tumor progression will be essential for
improving long-term survival in this disease. Consequently, the inhibition of pathways that allow
cells to survive therapy and eventually recur may be key to preventing the persistence of
disseminated tumor cells and subsequence relapse.
Although we were not able to demonstrate a requirement for Cerk in tumor recurrence
in orthotopic tumor recurrence assays, future experiments delineated in Chapter 4 are expected
to specifically address this question. This will help conclusively identify whether inhibition of
Cerk is likely to be a successful target for therapy in the context of cancer, specifically those
cancers refractory to chemotherapy or targeted therapy, in which Cerk inhibitors could be used
in combination therapy regimens.
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Materials and Methods
Animals and Orthotopic Recurrence Assays
All animal experiments were performed in accordance with guidelines of the
Institutional Animal Care and Use Committee at the University of Pennsylvania. Orthotopic
recurrence assays and competition assays were performed as described (49,198). Athymic
(nu/nu) mice were obtained from Taconic (Germantown, NY). Mice treated with tamoxifen
received 225 mg/kg tamoxifen by oral gavage for 1, 3 or 5 consecutive days.

Tissue Culture and Reagents
Primary MTB/TAN tumor cells were cultured as described in the presence of doxycycline
(49,198). Primary tumor cells were transduced with retrovirally-packaged shRNAs targeting
mCerk.

Caspase-Glo and CellTiter-Glo Assays
Viable cell number was measured using the CellTiter-Glo® Luminescent Cell Viability
Assay (Promega) and used to normalize caspase activity values measured with Caspase-Glo® 3/7
Assay System (Promega). Briefly, cells grown in 96-well white-bottom plates were treated with a
1:1 mixture of Caspase-Glo or CellTiter-Glo reagent and PBS (50μl per well), and gently shaken
protected from light for 30 min at RT. Luminescence was measured using a GloMax 96Microplate Luminometer (Promega) with an integration time of 0.5 s. Experiments were
performed in triplicate.
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Plasmids and RNAi
shRNAs targeting mCerk were designed using RNAi Central
(http://katahdin.cshl.org/siRNA/RNAi.cgi?type=shRNA) and purchased from Open Biosystems.
The following sequences were used: shCerk1 TGCTGTTGACAGTGAGCGCGCACTTGCTGGTATTCAT
CAATAGTGAAGCCACAGATGTATTGATGAATACCAGCAAGTGCTTGCCTACTGCCTCGGA; shCerk2
TGCTGTTGACAGTGAGCGAAGATTGTGTGTGTTACTCAACTAGTGAAGCCACAGATGTAGTTGAGTAACA
CACACAATCTG TGCCTACTGCCTCGGA. Oligonucleotides were cloned into the LMP vector (Open
Biosystems), modified to express H2B-eGFP (referred to as MLPHG in the text) or H2B-mCherry
as described (199).
shRNA plasmids were virally packaged using Plat-E cells (Morita et al., 2000), which were
transfected with retroviral constructs using Lipofectamine® 2000 (Life Technologies).
Supernatant containing viral particles was collected 48 hr post-transfection, filtered and used to
infect primary tumor cell lines. Transduction was performed in the presence of 4 µg/ml
polybrene (Millipore).

Antibodies
The following antibodies were used as indicated throughout the text: cleaved caspase-3
(Cell Signaling), cleaved PARP (Cell Signaling), Ki67 (Dako), β-Tubulin (Biogenex).

Immunoblotting
Protein lysates were generated by homogenizing cells in RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1% NP40, 0.5% NaDOC, 0.1% SDS) supplemented with HALTTM Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific).
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Secondary antibodies conjugated to IRDye 800CW (LI-COR Biosciences) were used.
Odyssey V3.0 system (LI-COR Biosciences) was used to visualize and quantify proteins of
interest. Quantification was performed using ImageStudio software (LI-COR Biosciences).

Immunofluorescence and Microscopy
For immunofluorescence studies of tumor tissue from the competition assay, tumors
were snap-frozen in OCT (TissueTek) and cut into 8 µm frozen sections. Sections were fixed in
4% PFA for 10 min then stained with Hoechst 33258 (Sigma).
For cell culture experiments, cells were seeded on 4-chamber slides, fixed in 4% PFA for
10 min then permeabilized with 0.5% Triton in PBS for 20 min. Slides were then stained with
corresponding primary and secondary antibodies. Fluorescence and immunofluorescence
microscopy were performed on a DM 5000B Automated Upright Microscope (Leica). Images
were captured with a DFC350 FX monochrome digital camera (Leica).

RNA Isolation and Quantitative RT-PCR
RNA was isolated from tumors using Trizol (Invitrogen) followed by RNeasy® RNA Mini
Kit (Qiagen). RNA was isolated from cells using the RNeasy® RNA Mini Kit (Qiagen). Reverse
transcription was performed using the High-Capacity cDNA Reverse Transcription kit (Applied
Biosystems) according to manufacturer’s instructions. qPCR was performed on the ViiaTM 7 RealTime PCR System (Life Technologies) using 6-carboxyfluorescein-labeled Taqman probes for
mCerk, hCerk, mTBP and hTBP (Applied Biosystems). Relative expression levels were calculated
using the comparative CT method.
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Total RNA was isolated from cells for detection of shRNAs using the miRNeasy® Mini Kit
(Qiagen). Reverse transcription was performed with custom primers for shCerk1, shCerk2 and
snoRNA202 as an internal control using the TaqMan® MicroRNA Reverse Transcription Kit (Life
Technologies). qPCR was performed on the ViiaTM 7 Real-Time PCR System (Life Technologies)
using 6-carboxyfluorescein-labeled Taqman probes for shCerk1, shCerk2 and SnoRNA202
(Applied Biosystems). Relative expression levels were calculated using the comparative CT
method.

Flow Cytometry
To measure the ratio of GFP- and mCherry-positive cells before and after 4-OHtamoxifen-induced recombination in vitro, cells were collected by trypsinization and fixed in 1%
formaldehyde and 0.04% sodium azide, washed, and analyzed on an LSRII flow cytometer (BD
Biosciences). Data were analyzed using FlowJo software.

Statistical Analyses
Unpaired Student’s t-tests were utilized to analyze normally distributed data. MannWhitney U tests were used when data were not normally distributed. Two-way ANOVAs were
used to compare paired data. Log-rank tests were used to analyze survival curves. p-values <
0.05 were considered statistically significant. Hazard ratios with 95% confidence intervals were
calculated for all survival curves.
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Figure 3.1. Cerk knockdown sensitizes tumor cells to apoptosis in vitro following HER2/neu
down-regulation
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(A) Representative fluorescence images and (B) quantification of MTB/TAN primary tumor cell
lines expressing empty vector, a control scrambled shRNA, shCerk1 or shCerk2 withdrawn from
doxycycline 72 hr then stained for cleaved caspase-3 (red; Hoechst = blue). (C) Quantification of
MTB/TAN primary tumor cell lines expressing empty vector, a control scrambled shRNA, shCerk1
or shCerk2 withdrawn from doxycycline 72 hr then stained for Ki67. (D) Western blot of
MTB/TAN primary tumor cell lines expressing empty vector, a control scrambled shRNA, or Cerk
shRNA1 withdrawn from doxycycline 48 hr, blotted for cleaved PARP, quantified in (E), and
cleaved caspase-3, quantified in (F). (G) Western blot of MTB/TAN primary tumor cell lines
expressing empty vector, a control scrambled shRNA, or Cerk shRNA2 withdrawn from
doxycycline 48 hr, blotted for cleaved PARP, quantified in (H), and cleaved caspase-3, quantified
in (I). *p<0.05, **p<0.01, ***p<0.001.

82

Figure 3.2. Cerk is required for tumor cell survival following HER2/neu down-regulation
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(A) qRT-PCR analysis of Cerk mRNA expression in Cerk knockdown tumor cell lines. (B) Schematic
of competition assay and timing of doxycycline treatment and tumor harvest. (C) Percentage of
eGFP-positive and mCherry-positive cells was determined at timepoints in (B) up to 28 days
post-deinduction. Data represent mean ± SEM. (D) Representative fluorescence images of
primary tumors, 96 hr deinduced tumors and residual lesions 28 days post-deinduction. (E)
Percentage of eGFP-positive and mCherry-positive cells at timepoints in (B) in control cohort and
(F) in a second shRNA cohort. *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.3. Cerk knockdown is not maintained in orthotopic recurrence assays

(A) Recurrence-free survival of nude mice harboring primary orthotopic tumors from MTB/TAN
primary tumor cell lines expressing empty vector, a control scrambled shRNA, shCerk1 or
shCerk2 induced to regress by doxycycline withdrawal. (B) qRT-PCR analysis of Cerk mRNA
expression in primary tumors formed from all cell lines in (A). (C) Recurrence-free survival of
nude mice harboring MTB/TAN primary cell lines expressing empty vector, a control scrambled
shRNA, shCerk1 or shCerk2 withdrawn from doxycycline 48 hr post-injection. (D) qRT-PCR
analysis of Cerk mRNA expression in recurrent tumors formed from all cell lines in (C).
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Figure 3.4. Characterization of FLIPi conditional shRNA expression system in vitro and
MTB/TAN;Ubc-CreERT2 cell line
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(A) Representative images of MTB/TAN;Ubc-CreERT2 cells transduced with FLIPi-shp53 construct
treated with 4-OH-tamoxifen at indicated doses for 24 hr and (B) 48 hr. (C) Representative
hematoxylin and eosin stained sections from primary MTB/TAN;Ubc-CreERT2 tumors. (D)
Recurrence-free survival of nude mice harboring primary orthotopic tumors from
MTB/TAN;Ubc-CreERT2 cells induced to regress by doxycycline withdrawal.
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Figure 3.5. Characterization of FLIPi conditional shRNA expression system and MTB/TAN;UbcCreERT2 cell line in vivo
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Dissection images of primary orthotopic tumors generated from injection of MTB/TAN;UbcCreERT2 FLIPi-shp53 cells, (A) untreated or treated with vehicle, (B) treated with tamoxifen for 1
d, (C) treated with tamoxifen for 3 d, and (D) treated with tamoxifen for 5 d.
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Figure 3.6. Conditional Cerk knockdown is not obtained using FLIPi system in vivo

Recurrence-free survival of nude mice harboring primary orthotopic tumors from
MTB/TAN;Ubc-CreERT2 primary tumor cell lines conditionally expressing FLIPi empty vector, a
control scrambled shRNA, shCerk1 or shCerk2, (A) induced to recombine with 3 d tamoxifen
treatment or (B) treated with vehicle, then induced to regress by doxycycline withdrawal. (C)
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qRT-PCR analysis of Cerk mRNA expression in primary tumors, tumors withdrawn from
doxycycline for 96 h, and recurrent tumors formed from all cohorts in (A) and (B).
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Figure 3.7. MTB/TAN;Ubc-CreERT2 cells undergo efficient recombination upon treatment with
tamoxifen but express low levels of shRNA

(A) Flow cytometric analysis of MTB/TAN;Ubc-CreERT2 primary tumor cell lines before
recombination (untreated) or following Cre-mediated recombination (treated with 4-OHtamoxifen). (B) qRT-PCR analysis of Cerk mRNA expression in MTB/TAN primary tumor cell lines
constitutively expressing MLPHG empty vector, a control scrambled shRNA, shCerk1 or shCerk2,
and MTB/TAN;Ubc-CreERT2 primary tumor cell lines transduced once (1x) or twice (2x) with FLIPi

92

empty vector, a control scrambled shRNA, shCerk1 or shCerk2 then induced to recombine with
4-OH-tamoxifen treatment.
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Figure 3.8. High dose NVP-231 treatment may synergize with lapatinib in HER2/neu–amplified
human breast cancer cells

BT474 and SKBR3 cells were treated with 100 nM lapatinib or DMSO and increasing doses of
NVP-231 from 100 nM to 3 µM for 16 h (A)(D), 24 h (B)(E), or 48h (C)(F). Caspase activity values
were measured with Caspase-Glo® 3/7 Assay System and normalized to viable cell number
measured using the CellTiter-Glo® Luminescent Cell Viability Assay.
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Figure 3.9. Growth curve cannot delineate role for Cerk in primary or recurrent tumor growth

(A) qRT-PCR analysis of Cerk knockdown in primary (54074) and recurrent (42929 and 48316)
MTB/TAN cell lines expressing empty vector, a control scrambled shRNA, shCerk1 or shCerk2.
Growth curve demonstrating tumor volume over time for primary orthotopic tumors from (B)
primary MTB/TAN cell lines (54074), (D) 42929 recurrent MTB/TAN cell lines and (F) 48316
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recurrent MTB/TAN cell lines. Mean growth rates for (C) primary MTB/TAN cell lines (54074), (E)
42929 recurrent MTB/TAN cell lines and (G) 48316 recurrent MTB/TAN cell lines.
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CHAPTER 4: Summary and Future Directions
Summary
The ability of tumor cells to survive adjuvant or neoadjuvant therapy and persist in
patients leads to breast cancer recurrence, and recurrence in turn is responsible for the majority
of morbidity and mortality associated with breast cancer. Understanding pathways involved in
tumor cell survival following therapy will provide insight into effective treatments to eliminate
tumor cells during primary therapy thereby preventing breast cancer recurrence. In this thesis,
we propose Ceramide Kinase as a novel target that is functionally involved in tumor cell survival
following therapy.
First we demonstrated that Cerk is spontaneously up-regulated in recurrent mammary
tumors of inducible bitransgenic mouse models of breast cancer recurrence driven by four
different oncogenes – HER2/neu, c-MYC, Wnt1 and Akt1. Having observed this up-regulation in
vivo upon oncogene down-regulation, we then determined that Cerk is up-regulated in vitro in
MTB/TAN cell lines following HER2/neu down-regulation, as well as in human HER2/neuamplified breast cancer cells following HER2/neu pathway inhibition with lapatinib. We also
demonstrated that chemotherapeutic treatment with adriamycin leads to acute Cerk upregulation in mouse and human breast cancer cells.
We then showed that Cerk up-regulation has the functional consequence of promoting
tumor cell survival in vitro following HER2/neu down-regulation. Furthermore, Cerk promotes
tumor cell survival in vivo acutely following HER2/neu down-regulation. As a result, Cerk
promotes mammary tumor recurrence in vivo.
Additionally, we interrogated human breast cancer patient datasets to determine
whether CERK expression was predictive of outcome. We found that elevated CERK expression
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was associated with an increased risk of recurrence in women with breast cancer. We also found
that high CERK expression was associated with aggressive subtypes of breast cancer, including
those with ER-negative status, PR-negative status, HER2-positive status, high tumor grade, and
ErbB2 and basal-like tumors. We also found that the association between CERK expression and
relapse-free survival in breast cancer patients was independent of the association between
CERK expression and these aggressive tumor subsets.
In loss of function studies, we sought to further our understanding of the potential
usefulness of targeting Cerk in cancer. We found that Cerk knockdown sensitizes tumor cells to
apoptosis in vitro following doxycycline withdrawal and HER2/neu down-regulation, as seen by
increases in cleaved caspase-3 detected by immunofluorescence and Western blot.
Furthermore, we found Cerk knockdown cells are strongly selected against following HER2/neu
down-regulation in vivo. We hypothesize that the paracrine secretion of PGE2 may be involved
in maintaining Cerk knockdown cells in primary tumors in the competition assay setting. This will
have to be confirmed by experiments outlined in the next section (Future Directions). Secreted
PGE2 may allow Cerk knockdown cells to persist in primary tumors in a setting where Cerk
knockdown was previously determined to be lost. Cell-autonomous mechanisms may
overwhelm the dependence on paracrine factors upon HER2/neu down-regulation, as Cerk
knockdown cells were selected against very strongly within 96 hr despite the presence of control
cells.
We then wished to determine whether Cerk is required for tumor recurrence by
performing Cerk knockdown recurrence assays. Due to difficulty maintaining knockdown using
Cerk shRNAs, we were not able to answer this question using constitutive knockdown systems.
We then turned to the FLIPi conditional shRNA expression system in an attempt to circumvent
98

selection events occurring against Cerk knockdown. We tested FLIPi in an MTB/TAN;Ubc-CreERT2
cell line in vitro then in vivo, demonstrating that FLIPi was able to undergo efficient and tightlyregulated recombination upon treatment with tamoxifen.
Having optimized this system, we sought to address the initial question of whether Cerk
was required for tumor recurrence by inducing recombination at deinduction, when doxycycline
is withdrawn and HER2/neu is down-regulated. Unfortunately, we were not able to address the
requirement for Cerk in tumor recurrence as no knockdown was detectable in any cohort
irrespective of shRNA expression or treatment regimen. This system holds promise but will
require further troubleshooting to answer the question of the requirement for Cerk in tumor
recurrence.
As genetic knockdown of Cerk proved technically challenging, we attempted to use the
small molecule inhibitor of Cerk NVP-231 to test whether it would sensitize HER2/neu–amplified
human breast cancer cells to lapatinib treatment. We found that high dose NVP-231 treatment
may synergize with lapatinib, but as the doses were very high this effect may not be attributable
solely to inhibition of Cerk.
Lastly, having demonstrated a role for Cerk acutely upon oncogene down-regulation, we
wanted to determine whether Cerk was required for actively proliferating primary and recurrent
tumors. Although we saw no effect of Cerk knockdown on tumor growth rates, these results are
inconclusive as Cerk knockdown was not shown to be maintained throughout the course of the
experiment.
The difficulty of maintaining Cerk knockdown in orthotopic recurrence assays in vivo
may indicate a strong dependence of tumor cell lines on Cerk signaling, which in turn may
indicate that Cerk has potential as a drug target in cancer cells. In aggregate, our findings
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identify Cerk signaling as a pathway for cell survival in breast cancer cells that is sufficient to
promote tumor recurrence. Additionally, we find that Cerk kinase activity is required for its
effect promoting tumor cell survival. Moreover, we demonstrate a requirement for Cerk upon
HER2/neu down-regulation as Cerk knockdown cells are subjected to strong negative selection
in this context. We also find that high CERK expression defines a subset of human breast cancers
with a high likelihood of relapse.
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Future Directions
Characterize Cerk protein expression in cell lines and tumors
Although several antibodies have been synthesized against human CERK and are
commercially available, two of which were predicted to have cross-reactivity against mouse,
neither detected mouse Cerk in our hands (data not shown). As a result, we sought to generate
a custom antibody for Cerk. Several attempts to generate purified full-length recombinant Cerk
in bacteria and insect cells failed (data not shown). Consequently, we chose to use a peptidebased approach to generate an antibody against Cerk.
A C-terminal peptide identified by Open Biosystems (now Thermo-Fisher) was chosen
for synthesis and immunization into two rabbits. Early bleeds (day 35, 56/58, 104, 145, 215 and
264) from these rabbits have been tested for reactivity against mouse Cerk, and all bleeds from
both rabbits detect overexpressed Cerk in cell lysates and immunoprecipitated HA-tagged Cerk.
Purification was completed on bleeds from days 35, 56/58 and 104 from each rabbit
independently, yielding two purified antibodies. Both antibodies also detected overexpressed
Cerk in lysates and immunoprecipitated HA-tagged Cerk. It is unclear at this time whether the
purified antibodies are capable of recognizing endogenous Cerk in cell and tumor lysates.
Additional testing and characterization of these Cerk antibodies will be necessary before
they can be of use. First, these antibodies need to be tested for immunoprecipitation of
overexpressed, and subsequently endogenous, Cerk protein from cell lysates. The ability to
immunoprecipitate Cerk may solve the issues of detection of endogenous protein by eliminating
other proteins and concentrating Cerk. We have attempted immunoprecipitation with both
purified Cerk antibodies and saw that they appear to be capable of immunoprecipitation.
However, this has not been successfully repeated, so this experiment will require optimization.
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Furthermore, later bleeds need to be tested for titer, and if their titer is higher than
earlier bleeds then their purification will likely yield antibodies with higher avidity. Once a
functional antibody has been optimized, then analysis of Cerk protein expression will be
possible. Testing Cerk antibodies for immunofluorescence will also help provide key insights, as
many questions about tumor heterogeneity as well as sub-cellular localization could be
answered with immunofluorescence.
First, Cerk expression patterns will need to be assessed by performing Western blots on
tumor lysates from primary and recurrent tumors of MMTV-rtTA;TetO-HER2/neu, MMTVrtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 mice. Additionally,
immunofluorescence with this antibody will confirm changes in expression as well as help
identify heterogeneity within tumors. This may identify regions of primary tumors with high
levels of Cerk prior to oncogene down-regulation.
Additionally, using the Cerk antibody, we will assess the changes of Cerk expression in
response to HER2/neu down-regulation in vitro and in vivo to determine whether it follows
mRNA up-regulation. We will also assess changes of Cerk protein expression in response to
chemotherapy by treating MTB/TAN cell lines with adriamycin.

Characterize ceramide-1-phosphate levels in cell lines and tumors
An important question needing to be address is whether the product of Cerk, ceramide1-phosphate (C1P), is altered in proportion to Cerk protein levels. Specifically, when Cerk is
overexpressed, C1P levels are expected to increase, and when Cerk is knocked down, C1P levels
are expected to decrease. C1P is the only known product of Cerk, so the functional effect of Cerk
is believed to be through its modulation of C1P and consequently ceramide levels. Confirming
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this by assessing levels of C1P in cells and tumors where Cerk expression has been altered will
help confirm or disprove that C1P is mediating the effects of Cerk on tumor cell survival and
tumor recurrence.
We addressed this question by liquid chromatography tandem mass spectrometry (LCMS/MS) in collaboration with the laboratory of Ian Blair (performed by Nate Snyder). We
performed Folch lipid extractions of MTB/TAN cells with Cerk overexpression or Cerk
knockdown. This was followed by liquid chromatography optimized for ceramides and tandem
mass spectrometry on a TSQ Quantum Ultra™ Triple Stage Quadrupole Mass Spectrometer
(Thermo Scientific), based on previously published protocols (226,227). Unfortunately, although
we analyzed all species of C1P and ceramide between C12 and C22, we did not detect changes
in C1P or ceramide that were consistent with levels of Cerk expression (assessed by mRNA).
There are many possible explanations for the lack of changes observed, including the
conditions in which cells were cultured. In normal culture conditions, the ceramide rheostat may
be able to compensate for levels of Cerk and maintain physiological levels of C1P and ceramide.
However, if the cells were placed in conditions of stress, such as serum deprivation, that are
known to lead to ceramide accumulation, this may reveal a change in C1P to ceramide balance.
These culture conditions may have to be optimized.
The extraction protocols will also require optimization to minimize loss of ceramides
thought to occur at several stages. Also, the LC-MS/MS protocols require optimization to
account for the phosphorylation state of C1P and the chain lengths of C1P being detected. Once
these steps have been optimized, this will allow for thorough characterization of C1P and
ceramide levels in cell lines and tumors. We will perform LC-MS/MS on lipids extracted from
primary and recurrent tumors of MMTV-rtTA;TetO-HER2/neu, MMTV-rtTA;TetO-MYC, MMTV103

rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 mice to determine whether C1P and
ceramide levels change as expected in correlation with Cerk protein levels. We will also assess
the changes of C1P and ceramide in response to HER2/neu down-regulation in vitro and in vivo
to determine whether they mirror predicted Cerk protein up-regulation. We will also measure
changes in C1P and ceramide in response to chemotherapy in MTB/TAN cell lines treated with
adriamycin.
Importantly, optimization of LC-MS/MS will allow us to determine conclusively whether
our G198D-Cerk mutant is truly kinase dead. A kinase assay will need to be performed in a cellfree system to test for kinase activity of G198D-Cerk relative to wildtype Cerk. Also, this will
allow us to address the possibility that G198D-Cerk may be dominant negative. This will be
tested by detecting levels of C1P and Cerk in cells where G198D-Cerk is expressed and
comparing to wildtype Cerk. If G198D-Cerk is dominant negative, it is expected that cells in
which it is expressed will have lower levels of C1P than control cells.
Together, these experiments will be very important in determining whether C1P is in
fact mediating the effects of Cerk or whether an additional level of complexity may need to be
investigated. If C1P is not found to mediate the effects of Cerk, this may indicate other roles for
Cerk which would have to be elucidated. Cerk may have other substrates yet to be identified.
Alternatively, Cerk may serve as a scaffolding protein or have other roles that have yet to be
characterized. These options will have to be investigated to understand whether inhibition of
kinase activity will be sufficient to prevent the pro-tumorigenic effects of Cerk, or whether other
classes of inhibitors will be needed.
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Determine the molecular mechanisms by which Cerk promotes tumor cell survival
Once C1P can be confirmed or disproven to be mediating the effects of Cerk expression
on tumor cell survival and tumor recurrence, the molecular mechanisms downstream will need
to be elucidated. Attempts to identify signaling pathways that are differentially regulated in
MTB/TAN cells with Cerk overexpression or Cerk knockdown following HER2/neu downregulation have not revealed any candidates (Figure 4.1). We investigated candidate pathways
based on many previously published reports, including cPLA2, PI3K/AKT, NF-κB, and MAPK.
Although these conditions demonstrated differential survival between MTB/TAN cells with Cerk
overexpression, control and Cerk knockdown vectors, we did not see any alterations in signaling
pathways, indicating the effect of Cerk on signaling pathways may be cell-type and context
specific.
Interestingly, cPLA2 protein levels and phosphorylation were found to be regulated by
HER2/neu expression, as doxycycline withdrawal led to decreased phospho- and total-cPLA2
levels, which has not been published (Figure 4.1A, B). Although this was not altered by levels of
Cerk expression, this constitutes a novel finding that merits further investigation.
In an attempt to interrogate potential pathways altered downstream of Cerk in a more
unbiased way, we turned to phospho-protein arrays. As we had found that Cerk has an effect on
cell survival, we identified phospho-protein arrays with many survival pathways, and chose
Sigma-Aldrich’s Panorama® Antibody Microarray-XPRESS Profiler725. Unfortunately, these
phospho-protein arrays only exist with antibodies with reactivity to human proteins, only a
fraction of which cross-react with mouse proteins. We decided to transition to human cell lines
to perform these phospho-protein arrays. We cloned seven shRNAs against CERK into the GIPZ
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vector, packaged them in lentivirus, transduced BT474 cells and tested them for CERK
knockdown. Three shRNAs yielded CERK knockdown of approximately 60% (Figure 4.2A).
Prior to utilizing BT474 CERK knockdown cell lines for phospho-protein arrays, we tested
them for candidate pathways following treatment with 100 nM lapatinib. No candidate
pathways appeared altered in DMSO or lapatinib treated cells between control and CERK
knockdown cells (Figure 4.2B-O). This indicates that either the levels of CERK knockdown
obtained were insufficient to result in a change in survival pathways downstream or that the
pathways tested may not regulate the effect of CERK in our system.
Future experiments will need to address these two possibilities. The generation of
BT474 cell lines with higher levels of CERK knockdown combined with the use of Sigma-Aldrich’s
Panorama® Antibody Microarray-XPRESS Profiler725 will help identify pathways downstream of
Cerk regulating its effect on cell survival in various contexts. Once candidate pathways have
been identified by phospho-protein arrays, they will have to be validated by Western blot then
confirmed by targeting those pathways to rescue apoptosis upon HER2/neu down-regulation.
Characterizing signaling downstream of Cerk and C1P will help advance the
understanding of the biology of tumors relying on this pathway and help identify the most
relevant way of inhibiting escape mechanisms in tumor recurrence.

Assess eicosanoid composition and involvement in tumor recurrence
As we hypothesized that PGE2 secretion may be involved in maintaining Cerk knockdown
tumor cells in the orthotopic competition assay, the question of eicosanoid composition and
contribution to tumor progression must be addressed. Mass spectrometry methods have been
developed to assess relative levels of many eicosanoids, particularly prostaglandins such as
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PGE2, in tumors (228). Assessing changes in eicosanoid composition based on Cerk levels
manipulated by overexpression, shRNA knockdown or germline knockout will help determine
whether these changes may be mediating downstream effects of Cerk. We anticipate that Cerk
overexpression will lead to increases in C1P levels and activation of cPLA2, which in turn will lead
to increases in secreted PGE2. This would indicate that the balance of eicosanoids such as
prostaglandins may be functionally involved in tumor recurrence. This will warrant further
investigation by genetic manipulation of cPLA2. Pharmacological approaches to inhibiting
eicosanoid synthesis could include administration of arachidonyl trifluoromethyl ketone
(AACOCF3), an inhibitor of cPLA2 (229), or more clinically relevant, inhibitors of the
cyclooxygenase (COX) and lipoxygenase (LOX) enzymes. COX and LOX inhibitors are currently in
clinical trials for their potential as chemopreventives.
If Cerk is found to be an upstream regulator of eicosanoid synthesis in mammary
tumors, it may offer a new way to target inflammatory signaling known to play a part in
tumorigenesis and tumor progression in many cancers. Cerk’s role in inflammation has been
identified, however, whether it has a functional role in cancer has not been addressed. These
experiments would be instrumental in determining Cerk’s potential as a drug target.

Determine whether Cerk is required for tumor recurrence
Despite many attempts delineated in Chapter 3, the question of Cerk’s requirement in
tumor recurrence still remains to be answered. This will need to be addressed either by
optimizing the FLIPi system or by identifying a new system to express Cerk shRNAs conditionally.
Upon recombination, the FLIPi vector generates a single transcript with the mCherry reporter
followed by the shRNA of interest in a miR30 setting. This transcript is then spliced due to the
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presence of splice donor and splice acceptor sites flanking the shRNA. This single transcript and
processing required to release the shRNA may be at fault in creating low levels of shRNA
transcript (Figure 3.7C, D).
To address these issues, the FLIPi vector could be rearranged so that the fluorescent
reporter is transcribed independently of the shRNA, hopefully leading to improved transcription
of shRNA and circumventing the potential issues with processing. Alternatively, we could turn to
other conditional expression systems such as pSico (230), and clone in a fluorescent reporter
that would be expressed following recombination.
With either approach, orthotopic recurrence assays will need to be performed to
address the requirement for Cerk in tumor cell survival upon HER2/neu down-regulation and in
tumor recurrence. Additionally, inducing recombination and expression of Cerk shRNAs at
various points will allow elucidation of the role of Cerk at each stage of tumor progression.
Additionally, the crossing of Cerk-/- mice with oncogene-induced cancer models needs to
be performed. This will provide strong evidence for the role of Cerk in the context of
tumorigenesis driven by specific oncogenes and tumor recurrence following oncogene downregulation. We propose crossing Cerk-/- mice with MMTV-rtTA;TetO-HER2/neu, MMTVrtTA;TetO-MYC, MMTV-rtTA;TetO-Wnt1;p53+/-, and MMTV-rtTA;TetO-Akt1 transgenic mice to
determine whether loss of Cerk will delay tumor recurrence in these models. If Cerk knockout
leads to delayed tumor recurrence in these mice, this will point to the possible utility of clinical
intervention in this pathway to prevent or treat recurrent breast tumors. If, however, knockout
of Cerk has no effect on tumor recurrence, compensatory pathways may be active in promoting
tumor cell survival upon oncogene down-regulation and in tumor recurrence, which may
indicate that Cerk would not be an ideal drug target for breast cancer patients.
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Conclusions
In aggregate, the proposed experiments will help to characterize CERK as a potential
drug target in the context of breast cancer, particularly breast cancer refractory to targeted
therapy. The ultimate hope would be to identify an inhibitor of CERK with good pharmacokinetic
and pharmacodynamics profiles. We could then determine whether CERK inhibition in
combination with chemotherapy and/or targeted therapy can overcome drug resistance in cell
lines, mouse models of breast cancer, and ultimately in breast cancer patients.

109

Figure 4.1. Cerk knockdown or overexpression in MTB/TAN cell line withdrawn from
doxycycline does not reveal differentially regulated signaling pathways
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(A) Western blot of MTB/TAN primary tumor cell lines expressing empty vector or Cerk shRNA2
withdrawn from doxycycline 72 hr, blotted for phospho- and total-cPLA2 quantified in (B),
phospho- and total-p65 quantified in (C), phospho- and total-p44/42 MAPK quantified in (D),
phospho- and total-Akt quantified in (E), and Bcl-xL quantified in (F). (G) Western blot of
MTB/TAN primary tumor cell lines expressing Cerk, empty vector or Cerk shRNA2 withdrawn
from doxycycline 72 hr, blotted for phospho- and total-cPLA2 quantified in (H), phospho- and
total-p65 quantified in (I), phospho- and total-Akt quantified in (J), phospho- and total-p44/42
MAPK quantified in (K), and Bcl-xL quantified in (L).

111

Figure 4.2. CERK knockdown in BT474 cell line treated with lapatinib does not reveal
differentially regulated signaling pathways
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(A) qRT-PCR analysis of CERK mRNA expression in CERK knockdown BT474 cell lines. (B) Western
blot of BT474 cell lines expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with
DMSO or lapatinib 4 hr, blotted for phospho- and total-HER2 quantified in (C), phospho- and
total-Akt quantified in (D), and Bcl-xL quantified in (E). (F) Western blot of BT474 cell lines
expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with DMSO or lapatinib 4 hr,
blotted for phospho- and total-p65 quantified in (G), and phospho- and total-p44/42 MAPK
quantified in (H). (I) Western blot of BT474 cell lines expressing control shFF3 or shCerk1,
shCerk2 or shCerk7 treated with DMSO or lapatinib 4 hr, blotted for phospho- and total-JNK
quantified in (J), and phospho- and total-Bcl-2 quantified in (K). (L) Western blot of BT474 cell
lines expressing control shFF3 or shCerk1, shCerk2 or shCerk7 treated with DMSO or lapatinib 4
hr, blotted for cleaved PARP (M), phospho- and total-GSK-3β quantified in (N), and total-IκBα
quantified in (O).
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